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CHAPTER 1

INTRODUCTION

1.1

Proteases and Toxin-Antitoxin Systems
Proteases are enzymes that catalyze the hydrolysis of peptide bonds in proteins

afeecting protein stability. Proteolysis is the physical breakdown of proteins into amino
acids or small polypeptides. Proteases are found in all organisms and perform a variety
of functions including: removal of irregular or nonfunctional proteins, inactivation of
regulatory proteins when necessary, and degradation of isolated proteins that are
normally associated with multi-protein complexes (Gottesman, 1996). Some proteases
found in bacteria can also be harmful to other organisms by acting as virulence factors.
Toxin-antitoxin (TA) systems, also referred to as plasmid addiction systems or
post-segregational killing (PSK) systems, help maintain low copy-number plasmids by
preventing plasmid-free daughter cells from surviving (Jensen and Gerdes, 1995). TA
systems usually contain a gene that encodes a stable toxin and a gene that encodes a
relatively unstable antitoxin located next to each other on an operon (Gerdes, 2000). The
differential stability of the toxin and antitoxin is a vital component in the addiction of TA
systems. As long as the antitoxin is present and is able to neutralize the toxin, the TA
system, and subsequently, the host organism proliferates. However, when the antitoxin is
degraded by a protease, the toxin is unveiled and the cell is arrested (Figure 1.1). The
	
  

1	
  

(a)
(b)

Figure 1.1: Plasmid Addiction
This figure shows a plasmid free bacterial cell (oval shape) that divides into
daughter cells as expected
This figure shows a bacterial cell containing an addictive plasmid (small circle
shaded blue). Daughter cells grow as expected as long as the plasmid is
maintained. However, if the plasmid is lost, the addiction phenomenon leads to
death of the plasmid-free cells (shown as X)
-Figure adapted from (Magnuson, 2007)

antitoxin must be degraded and at a faster rate than the toxin, in order for the addiction
phenomenon to occur. Due to their role in the stability of protein antitoxins, proteases
must therefore be considered a vital component in the function of TA systems. There are
several theories as to why TA systems are present in cells including the possibilities that
they are genomic junk, that they play a role in gene regulation, or that they play a role in
growth control (Magnuson, 2007). TA systems are divided into five categories based on
the type and the mode of action of their antitoxin (Van Melderen, 2010). These
categories are illustrated in Table 1.1.
1.1.1

Type I Toxin-Antitoxin Systems
Type I TA systems contain a toxic protein and a small RNA (sRNA) as their

antitoxin (Van Melderen and Saavedra De Bast, 2009). The sRNA is complementary to
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Table 1.1
Categories of Toxin-Antitoxin Systems
Type

Toxin

Antitoxin

I

protein

RNA

II

protein

protein

III

protein

RNA

IV

protein

protein

V

protein

protein

Antitoxin Mode of Action
Prevents toxin production by inhibiting
toxin mRNA translation
Directly binds the toxin to prevent
activity
Directly binds the toxin to inhibit activity
Antagonizes toxin activity without
interacting with the toxin; interacts with
the target
Prevents toxin production by cleaving
toxin mRNA

the toxin’s mRNA allowing it to bind and prevent translation of the toxin. Type I toxins
are usually hydrophobic proteins less than 60 amino acids long. Type I TA systems
appear to have evolved by lineage-specific duplication rather than by horizontal gene
transfer. Type I TA systems have been found in plasmids from both gram-positive and
gram-negative bacteria and can also be present on bacterial chromosomes (Fozo,
Makarova et al., 2010).
1.1.2

Type II Toxin-Antitoxin Systems
Type II TA systems consist of a protein as both their antitoxin and toxin and the

binding of the antitoxin to the toxin neutralizes its toxicity (Yamaguchi, Park et al.,
2011). Type II TA systems are found in both archaea and bacteria and appear to function
in quality control of gene expression (Pandey and Gerdes, 2005). These TA systems also
appear to aid in plasmid competition, by mediating the exclusion of competing plasmids
against the host-encoded plasmid (Cooper and Heinemann, 2000). Likely due to their
addictive properties, type II TA systems appear to be maintained even though they do not
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necessarily provide an advantage to their bacterial hosts and it is this addictive property
that contributes to the evolutionary stability and success of these TA systems (Leplae,
Geeraerts et al., 2011).
Type II TA systems are grouped into 9 toxin families based on their amino acid
sequence, the cellular processes they affect, and by their target as presented in
Table 1.2 (Van Melderen and Saavedra De Bast, 2009). Type II TA systems are
commonly organized in operons where the toxin gene is immediately preceded by the
antitoxin gene (Figure 1.2). The antitoxin binds to an operator site upstream of the genes
in order to negatively regulate the expression of the operon and the toxin enhances this
regulation by binding the antitoxin (Gerdes, Christensen et al., 2005). The antitoxin also
binds the toxin to neutralize it. There are several TA systems that fit into these regulatory
and functional mechanisms including the Phd/Doc system of the P1 plasmid, the
PemI/PemK system of the R100 plasmid, the CcdA/CcdB system of the F plasmid, and
the ParD/ParE system of the RK2/RK4 plasmid (Gerdes, 2000). Exceptions to these
mechanisms have been identified in other Type II TA systems. The HigA/HigB system
of the Rts1 plasmid has its gene order reversed and contains separate promoters for the
toxin and antitoxin (Tian, Hayashi et al., 1996) (Figure 1.3). The ω-ε-ζ system of
plasmid pSM19035 is unique because neither the toxin (Omega) nor the antitoxin
(Epsilon) are involved in regulation of their own synthesis (Zielenkiewicz and
Ceglowski, 2001) (Figure 1.4).
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Table 1.2
Examples of Type II Toxin-Antitoxin Systems

	
  

Toxin

Found In

Mode of Action

Source

CcdB

Escherichia
coli

Interrupts DNA replication by
targeting DNA gyrase

(Bernard and
Couturier, 1992)

ParE

Escherichia
coli

Interrupts DNA replication by
targeting DNA gyrase

(Jiang, Pogliano et al.,
2002)

VapC

Haemophilus
influenzae

Ribonuclease that is active on free
RNA but does not degrade DNA

(Daines, Wu et al.,
2007)

ζ

Streptococcus
pyogenes

Inhibits replication, transcription, and
translation ultimately leading to cell
death however, the toxin’s molecular
target(s) are currently unknown

(Lioy, Martin et al.,
2006)

RelE

Escherichia
coli

Cleaves mRNA in a
ribosome-dependent manner

(Pedersen, Zavialov et
al., 2003)

HigB

Vibrio
cholerae

Cleaves mRNA in a
ribosome-dependent manner

MazF

Escherichia
coli

Cleaves mRNA but is not
ribosome-dependent

HipA

Escherichia
coli

Doc

Escherichia
coli

Utilizes protein kinase activity to
affect translation
Proposed to associate with the 30S
ribosomal subunit to inhibit
translation

5	
  

(ChristensenDalsgaard and Gerdes,
2006)
(Christensen, Pedersen
et al., 2003)
(Correia, D'Onofrio et
al., 2006)
(Liu, Zhang et al.,
2008)

Figure 1.2: Type II Antitoxin/Toxin operon
The Type II Antitoxin/Toxin operon configuration I consists of the antitoxin gene
preceding the toxin gene. Both genes code for small proteins. The antitoxin is an
unstable protein and the toxin is stable. The two genes are coexpressed and the antitoxin
is always synthesized in excess of the toxin. As long as the antitoxin is present in the cell
it binds to and neutralizes the toxin. Upon plasmid loss, expression of both proteins
ceases. The continuing degradation of the antitoxin by the host-encoded protease causes
the antitoxin’s concentration to drop within the cell. The now free toxin can associate
with its cellular target and arrest cell growth.
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Figure 1.3: Type II Toxin/Antitoxin operon
The Type II Toxin/Antitoxin operon configuration II consists of the toxin gene preceding
the antitoxin gene, each with their own promoter. Both genes code for small proteins.
The antitoxin is an unstable protein and the toxin is stable. The antitoxin is always
synthesized in excess of the toxin. As long as the antitoxin is present in the cell it binds
to and neutralizes the toxin. Upon plasmid loss, expression of both proteins ceases. The
continuing degradation of the antitoxin by the host-encoded protease causes the
antitoxin’s concentration to drop within the cell. The now free toxin can associate with
its cellular target and arrest cell growth.
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Figure 1.4: Type II TA System Omega Epsilon Zeta Operon
This figure shows that in this Type II TA operon configuration III the antitoxin, epsilon,
is preceding the toxin, zeta, but that neither of them have any control over the regulation
of their own synthesis. The synthesis is regulated by the repressor, omega. The repressor
has its own promoter and the antitoxin and toxin have a different promoter. The Lon
protease is able to degrade epsilon when it is in its free state or when it is bound to zeta.
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1.1.3

Type III Toxin-Antitoxin Systems
Type III TA systems are uniquely characterized by having an RNA antitoxin

directly inhibit the toxin protein (Yamaguchi, Park et al., 2011). The ToxI-ToxN TA
system found in a plasmid in the plant pathogen Erwinia carotovora is an example of a
type III TA system. The antitoxin is the ToxI-RNA and it directly inhibits the ToxN
toxin. This ToxI-ToxN TA system is able to abort phage infections (Fineran, Blower et
al., 2009). The structure of ToxI-ToxN was solved by crystallographic analysis and
utilising this data, it was possible to perform structure-based homology searches that
identified three new type III TA system families for a total of 125 type III TA
systems (Blower, Short et al., 2012).
1.1.4

Type IV Toxin-Antitoxin Systems
The YeeVU toxin-antitoxin system was originally identified as a type II TA

system based on the operon arrangement of the YeeV toxin and the YeeU antitoxin
genes (Brown and Shaw, 2003). However, further investigations into the mechanisms of
action of these two proteins have caused them to become classified as a novel type IV TA
system (Masuda, Tan et al., 2012). The toxin, YeeV, was found to hinder cell division by
affecting two cytoskeletal proteins by inhibiting the GTPase activity and the
GTP-dependent polymerization of FtsZ and by inhibiting the ATP-dependent
polymerization of MreB, which leads to a disruption of cell morphology and eventually
lysis of the E. coli cells (Tan, Awano et al., 2011). The antitoxin, YeeU, instead of
binding to the toxin YeeV and neutralizing it, actually antagonizes its toxicity by
increasing the bundling of the cytoskeletal polymers of FtsZ and MreB, preventing their
inhibition by YeeV (Masuda, Tan et al., 2012).
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1.1.5

Type V Toxin-Antitoxin Systems
The GhoST toxin-antitoxin system has been classified as a type V TA system

based on the novel ability of the antitoxin, GhoS, to cleave the mRNA of the toxin,
GhoT. Another unique factor of this TA system is that it is controlled by the type II TA
system, MqsR/MqrA, whereby during times of stress the GhoS antitoxin is degraded by
the MqsR toxin. This allows the mRNA of GhoT to be translated resulting in free toxin
that forms ghost cells and increases the persistence of the TA system (Wang, Lord et al.,
2012).

1.2

Bacteriophage P1
P1 is a temperate bacteriophage first isolated from Escherichia coli (E. coli) in

1951 (Bertani, 1951). The genome of P1 is 93,601 base pairs in length and is composed
of at least 117 genes, 49 of these genes do not have homologous genes in any other
organism. The structure of P1 is similar to other phage with its icosahedral head (capsid)
attached to a tail with six kinked tail fibers and the tail consisting of a tail tube and a
contractile sheath (Lobocka, Rose et al., 2004). Since P1 is a temperate bacteriophage, it
can exist in either the lysogenic and lytic state inside the cell.
P1 infects E. coli and exists as a low copy number plasmid in the lysogenic state
with approximately one copy per bacterial chromosome (Lobocka, Rose et al., 2004). To
compensate for its low copy number, the P1 plasmid encodes several mechanisms to
ensure that the plasmid is passed on to daughter cells. The RepA protein regulates
replication, which proceeds bidirectionally after beginning at the oriR site, to make
certain that the plasmid divides along with the host genome (Chattoraj, Snyder et al.,
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1985). Since replication generates homologous pairs of DNA structures inside the same
cell, it is possible for recombination to occur between sister DNA strands forming a
dimer and if the cell divides before the dimer is resolved then one of the daughter cells
could be plasmid free. The cre-lox recombinase system prevents the formation of stable
dimers to help maintain the existence of the plasmid (Austin, Ziese et al., 1981). P1 also
utilizes the ParABS partition system as another method of plasmid maintenance which
ensures partitioning of a plasmid molecule to each daughter cell (Martin, Friedman et al.,
1987).
In the lytic state, P1 begins replication at oriL by a regular bidirectional theta
replication but then later switches to a rolling circle method of replication (Cohen, Or et
al., 1996). The rolling circle method of replication produces DNA concatamers, which
P1 cleaves at specific pac sites utilizing the pacase protein. The cleaved DNA is then
unidirectionally fed into the phage head until it is full (Sternberg and Coulby, 1987).
P1 is capable of generalized transduction, which was first observed in
1955 (Lennox, 1955). Generalized transduction allows for the movement of selected
genes between bacterial strains and P1 has been the main vehicle for this event due to its
ability to package large blocks of non-specific DNA into its capsid (Miller, 1992). P1 is
capable of binding to and injecting DNA into a wide range of bacterial species (Lobocka,
Rose et al., 2004).
1.2.1

The Phd-Doc Plasmid Addiction System
Plasmid addiction is a phenomenon in which the life of a cell is drastically

affected by the loss of a plasmid (Figure 1.1). Plasmids, such as P1, whose loss induces
this phenomenon are said to be addictive. The bacteriophage P1 plasmid addiction
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operon (Figure 1.5) is a toxin-antitoxin system encoding two proteins, Phd and Doc,
regulated by the Pr92 promoter. Phd stands for prevents host death and is the antitoxin
protein. Doc stands for death on curing and is the toxin protein. This system is able to
increase plasmid stability by arresting plasmid-free daughter cells of E. coli. This
phenomenon has been termed plasmid addiction. As long as the plasmid is retained, Phd
is able to bind and neutralize Doc (Lehnherr, Maguin et al., 1993). When plasmid loss
occurs, Phd is degraded by the ClpXP protease and is not replenished by new protein
synthesis. This causes the toxin, Doc, to be revealed and then Doc arrests the
cell (Lehnherr and Yarmolinsky, 1995).
1.2.2

The Doc Protein
The Doc protein is a fairly stable 126 amino acid protein encoded by the doc gene

of the P1 plasmid addiction operon (Lehnherr, Maguin et al., 1993). The main function
of Doc seems to be to inhibit protein synthesis but the actual target is currently
unknown (Hazan, Sat et al., 2001). While Doc cannot repress transcription of the
addiction operon alone, it does enhance this repression when it is bound to
Phd (Magnuson, Lehnherr et al., 1996). DocH66Y is a non-toxic version of Doc that
retains the ability to bind to Phd and enhance the transcriptional repression of the
addiction operon (Magnuson and Yarmolinsky, 1998).
1.2.3

The Phd Protein
The Phd protein is a relatively unstable 73 amino acid protein with a half-life of

approximately 30-60 minutes (Gottesman, 1996). The Phd protein is encoded by the phd
gene of the P1 plasmid addiction operon. The main function of Phd is to bind to and
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Figure 1.5: Model of the P1 plasmid addiction operon
The P1 plasmid addiction operon consists of two genes labeled antitoxin and toxin, which
encode two small proteins. Phd is the unstable antitoxin. Doc is the stable toxin. The
two genes are coexpressed and the antitoxin is always synthesized in excess of the toxin.
As long as Phd is present in the cell it binds to and neutralizes Doc. Upon plasmid loss,
expression of Phd and Doc ceases. The continuing degradation of Phd by the
host-encoded ClpXP protease causes the Phd concentration to drop within the cell. Free
Doc can then associate with its cellular target and arrest cell growth. Phd also acts as a
repressor by binding to the operator to repress transcription. Doc acts as a co-repressor
by enhancing this repression.
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neutralize Doc (Lehnherr, Maguin et al., 1993). Phd also has the ability to repress
transcription of the addiction operon approximately 10-fold as shown in LacZ fusion
experiments by binding as a dimer to the promoter region of the operon through DNA
contacts (Magnuson, Lehnherr et al., 1996).
Portions of Phd have been identified that are necessary for specific activities. The
N-terminal 54 amino acids confer repressor activity (Smith and Magnuson, 2004). Point
mutations in specific sites of the C-terminal half can interfere with repression (McKinley
and Magnuson, 2005). The C-terminal 24 amino acids are sufficient to confer antitoxin
activity, but lack repressor activity (Smith and Magnuson, 2004). A specificity
determinant for operator DNA binding was found to be located at Phd’s 7th amino
acid (Zhao and Magnuson, 2005).
Phd is degraded by the ClpXP protease (Lehnherr and Yarmolinsky, 1995). The
specific amino acids of Phd required for its recognition and degradation are currently
unknown. Identification of these recognition signals will increase our understanding of
the underlying mechanisms involved in ClpXP targeting. Understanding how ClpXP
recognizes and degrades Phd will also improve our understanding of the regulation and
control of the P1 plasmid addiction system, since without degradation of Phd by ClpXP,
the P1 toxin-antitoxin system shows no addictive effects.

1.3

The ClpXP Protease
The ATP-dependent Clp protease of E. coli consists of two subunits, ClpP and

ClpX (Gottesman, Clark et al., 1993). The ClpP subunit contains the proteolytic active
site, while the ClpX subunit, which possesses ATPase activity and molecular chaperone
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capability, activates the proteolytic activity of ClpP (Gottesman, Clark et al., 1993;
Maglica, Kolygo et al., 2009). Protein substrates are specifically recognized by the Clp
ATPase component and then threaded through the apical pore of the protease component
and into the proteolytic chamber (Hoskins, Yanagihara et al., 2002). Small peptides can
be degraded by ClpP alone, but larger substrates and folded proteins must be unfolded
and then presented to ClpP by ClpX in order to be degraded efficiently (Jennings, Bohon
et al., 2008).
ClpXP is classified as a serine protease. Serine proteases make up almost
one-third of all bacterial proteases, which are divided into five groups. They are called
serine proteases because they have a Serine (S) residue at their active site and they use a
catalytic triad consisting of S, Histidine (H), and Aspartic acid (D) residues in their
substrate-binding pocket to hydrolyze peptide bonds (Hedstrom, 2002).
1.3.1

ClpXP Structure
ClpP consists of two seven-membered rings stacked face-to-face (Wang, Hartling et

al., 1997). These rings enclose a central chamber containing the 14 active sites of the
enzyme. The X-ray structure of ClpP (Figure 1.6) revealed a cylindrical-shaped
tetradecamer (14 subunits) that was approximately 300kDa in molecular weight and 90 Å
in both height and diameter (Yu and Houry, 2007). The x-ray structure also indicated
that each monomer of ClpP (Figure 1.7) contains six repeats of α/β-fold units and one
protruding α/β unit which form the axial loop, head domain, and handle region of each
monomer (Wang, Hartling et al., 1997). The subunits of the ClpP tetradecamer are held
together mostly by hydrophobic interactions and the handle regions of each monomer
mediate ring-ring interaction (Yu and Houry, 2007) It appears that single, heptameric
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Figure 1.6: Structural Views of the ClpP Compartmental Peptidase
The top panel shows each of the 14 identical subunits of ClpP, colored blue to red from
the N terminus to the C terminus. The top view shows the 7-fold symmetry of a single
ClpP ring and the side view shows the face-to-face stacking of both ClpP rings. The
bottom panel shows cutaway diagrams illustrating the positions of the active site residues
(yellow) within the degradation chamber. Figure reprinted by permission from (Sauer,
Bolon et al., 2004)
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Figure 1.7: Monomeric and Tetradecameric ClpP Structure
A) Shows a ClpP monomer from E. coli including the axial loop, the head domain, and
the handle region as well as the six repeating α/β-fold units and the single protruding α/β
unit. B) Shows a side and top view of the tetradecameric (14 subunits) ClpP with a ClpP
monomer highlighted in blue. Figure reprinted by permission from (Yu and Houry, 2007)
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rings of ClpP are formed first and then two of these rings associate to form the doublestacked rings via the intercalation of the handle regions (Kress, Maglica et al., 2009; Yu
and Houry, 2007).
ClpX is a nucleotide-stabilized hexamer formed from six monomers as seen in
Figure 1.8 (Grimaud, Kessel et al., 1998). Each subunit of ClpX contains an ATPase
core domain in its N-terminus (Kim and Kim, 2003). The C-terminus contains the sensor
and substrate discrimination (SSD) domain, which plays a critical role in the recognition
of correct substrates by ClpX (Smith, Baker et al., 1999). A tripeptide comprised of
Isoleucine (I), Glycine (G), and Phenylalanine (F) was found to project out of the ClpX
C-terminus in the form of loops and this IGF tripeptide region is essential for ClpP
recognition (Kim, Levchenko et al., 2001).
There is one IGF region/loop per ClpX hexamer and all six IGF loops are required
for binding to ClpP (Martin, Baker et al., 2007). The other critical component for ClpXP
binding is the ClpP N-terminal axial loops, which bind to sites in ClpX (Figure 1.9).
Since ClpP is a heptamer and ClpX is a hexamer, both the ClpP N-terminal axial loops
and the ClpX IGF loops must adopt different conformations within each monomer to
access their specific binding sites (Gribun, Kimber et al., 2005). ClpXP preparations
show that ClpP was flanked on either one or both sides by a ring of ClpX. ClpX binds
tightly to ClpP, but only in the oligomeric state stabilized by nucleotide
binding (Grimaud, Kessel et al., 1998).
1.3.2

ClpXP Function
ClpP can degrade small peptides by itself and recent data suggests ClpP can

degrade larger substrates but at a reduced rate (Jennings, Bohon et al., 2008). In order to
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Figure 1.8: Crystal structure of nucleotide-bound hexameric ClpX
The structure shown here illustrates the asymmetry of the ClpX hexamers. Each color
represents one of the six subunits and each subunit contains both a small and large
domain. The asymmetry arises from large changes in rotation between the large and
small domains. These differences prevent nucleotide binding to two subunits, generate a
staggered arrangement of ClpX subunits and pore loops around the hexameric ring, and
provide a mechanism for coupling conformational changes caused by ATP binding or
hydrolysis in one subunit to flexing motions of the entire ring. Figure reprinted by
permission from (Glynn, Martin et al., 2009)
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Figure 1.9: ClpP and ClpX Binding
IGF loops of ClpX are shown as orange extensions bound to the cyan ellipses on the ClpP
unit. The axial loops of ClpP are shown as white and cyan loops protruding out of the
top of the ClpP unit bound to the orange ellipses of ClpX. The white loop at the front and
center position of ClpP is shown in the unbound state. The cyan ellipse on the top right
side of ClpP is shown as an empty binding site for an IGF loop. Figure reprinted by
permission from (Gribun, Kimber et al., 2005)
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fully degrade a substrate, ClpP must be in conformation with ClpX. The ClpX subunit of
the ClpXP protease serves as the recognition determinant, molecular chaperone, and
unfoldase for substrates (Baker and Sauer, 2006). Once ClpX has bound and unfolded a
substrate, it translocates the substrate into the axial pore of ClpP (Hoskins, Yanagihara et
al., 2002). The proteolytic activity of ClpP is activated by the binding of ClpX and by the
translocation of a substrate into its proteolytic core (Maglica, Kolygo et al., 2009). Once
inside the ClpP subunit, substrates are degraded into short peptides and are thought to be
released through side pores formed in ClpP as shown in Figure 1.10 (Sprangers, Gribun
et al., 2005).
1.3.3

Substrates of ClpXP
ClpXP has been found to degrade a number of substrates found in E. coli. One of

those substrates is the λO protein, which is the initiator protein of the bacteriophage
λ DNA replication system (Wojtkowiak, Georgopoulos et al., 1993). ClpXP also
degrades RpoS, which is the regulator protein of the σS subunit in E. coli RNA
polymerase (Schweder, Lee et al., 1996). ClpXP degrades bacteriophage Mu proteins
such as the MuA transposase and the virulent form of the Mu repressor (Jones, Welty et
al., 1998; Welty, Jones et al., 1997). ClpXP degrades the UmuD’ protein found in the
error-prone DNA polymerase, pol V (Gonzalez, Rasulova et al., 2000). ClpXP also
degrades Phd of the P1 plasmid addiction system (Lehnherr and Yarmolinsky, 1995).
The ClpX subunit of the ClpXP protease is the recognition determinant and five
classes of ClpX recognition signals have been identified. The first two types are
considered to be C-terminal motifs. They are distinguished by the types of residues
found at the C-terminus of their substrates (Flynn, Neher et al., 2003). These include
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Figure 1.10: ClpXP Function
In this figure, ClpX is represented as an ellipse called Chaperone. ClpX/Chaperone binds
to ClpP and unfolds the substrates, which are then translocated into ClpP through axial
pores. ClpP degrades the substrates into short peptides. These peptides are thought to be
released through side pores of ClpP. Figure reprinted by permission from (Yu and
Houry, 2007)
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substrates that have non-polar side chains and/or hydrophobic C-terminal residues that
are recognized by ClpX (Levchenko, Smith et al., 1997). The other three types of
recognition motifs are N-terminal motifs and are presented in Table 1.3 (Flynn, Neher et
al., 2003).

Table 1.3
ClpXP N-terminal Recognition Motifs
Ø indicates a hydrophobic side chain; X indicates any residue
Motif Name
N-motif 1
N-motif 2
N-motif 3

1.3.4

Order of Recognized Residuesa
NH2...polar-Thr/Ø-Ø-basic-Ø
NH2-Met-basic-Ø-Ø-Ø-X5-Ø
NH2…Ø-X-polar-X-polar-X-basic-polar

Source
(Flynn, Neher et al.,
2003)

Accessory Specificity Factors
Degradation of some ClpXP substrates requires additional or accessory specificity

factors. One such accessory specificity factor is the response regulator protein,
RssB (Becker, Klauck et al., 1999). Another accessory specificity factor is the stringent
starvation protein, SspB (Levchenko, Seidel et al., 2000).
1.3.4.1 RssB
RssB controls the stability of RpoS, which is the regulator protein of the
σS subunit in E. coli RNA polymerase (Muffler, Fischer et al., 1996; Schweder, Lee et al.,
1996). Sigma (σ) factors are proteins needed only to initiate RNA synthesis of specific
genes and the σ factor will vary depending upon the environmental signals present and
the gene to be transcribed. The rpoS gene codes for σS, which is the stationary/starvation
phase sigma factor (Sharma and Chatterji, 2010).
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Experiments were performed to determine if RssB-mediated regulation of RpoS
degradation reflected regulation of the protease, ClpXP, or of the substrate. It was
determined that RssB acts in a substrate-specific fashion and modulates RpoS activity as
well as its degradation (Zhou and Gottesman, 1998). The RssB response regulator was
found to directly target σS from rpoS for degradation by forming a stable complex
between σS, RssB, and ClpXP (Figure 1.11). The complex degrades σS and releases RssB
from ClpXP in an ATP-dependent reaction (Zhou, Gottesman et al., 2001).
Phosphorylation of RssB by acetyl phosphate stimulates the σS degradation (Bougdour,
Wickner et al., 2006). This reveals a mechanism for regulated protein turnover in which
a unique targeting protein, whose own activity is regulated through specific signaling
pathways, catalyzes the delivery of a specific substrate to a specific protease (Zhou,
Gottesman et al., 2001).
1.3.4.2 SspB
In order for ClpXP to be able to recognize and then degrade certain substrates, a
specificity-enhancing factor in the form of a tag must be on the substrate (Levchenko,
Seidel et al., 2000). The ClpXP protease, in particular, recognizes the SsrA-tagging
system. Interruption of translation of polypeptides in E. coli can lead to the addition of
an 11-residue carboxy-terminal peptide tail to the nascent chain. The addition of this tail
or tag is mediated by SsrA RNA, which is also known as 10Sa RNA or tmRNA
(Gottesman, Roche et al., 1998). tmRNA is a specialized RNA that has properties of
both tRNA and mRNA.
Ribosomes stall when their A-site is empty. This occurs because the end of the
mRNA has been reached and there was not a stop codon present, termination of
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Figure 1.11: RssB aids ClpXP in the Degradation of σS
In exponentially growing cells, RssB delivers σS to ClpXP for degradation. During the
reaction, RssB itself is not consumed; RssB acts catalytically and is able to carry out
multiple cycles of σS binding and delivery to ClpXP. Phosphorylation of RssB stimulates
σS degradation. Figure adapted and reprinted by permission from Cold Spring Harbor
Laboratory Press (Bougdour, Wickner et al., 2006)
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translation was inefficient, or levels of tRNA required to decode the A-site codon were
too low. However, it is possible to rescue the stalled ribosomes in each of these cases by
the use of tmRNA. The tRNA-like portion of tmRNA can act as a normal tRNA and
accept the nascent polypeptide. Next, the ribosome switches from the stalled mRNA to a
small open-reading frame (ORF) in the tmRNA and then translation can resume and
continue to a stop codon. This allows translation to terminate and the ribosome can be
recycled (Moore and Sauer, 2005).
The SsrA tag is added to certain proteins and protein fragments found in E. coli to
tag them for proteolysis (Gottesman, Roche et al., 1998). A ribosome-associated protein,
SspB, was found to bind specifically to SsrA-tagged proteins and to enhance recognition
of these proteins by ClpXP (Levchenko, Seidel et al., 2000). The zinc-binding domain of
ClpX contains the essential site for binding of the SspB protein to ClpX (Donaldson,
Wojtyra et al., 2003). SspB is tethered to ClpX in both the ATP and ADP bound enzyme
states whereas the ssrA-tag is only interacting with ClpX when it is in the ATP state.
After ATP is hydrolyzed, ClpX applies a pulling force to both the ssrA-tag and the SspB
protein, which ultimately results in degradation of the ssrA-tag and substrate and
disassociation of the SspB adaptor protein (Bolon, Grant et al., 2004). Cells with an sspB
mutation are defective in degrading SsrA-tagged proteins, demonstrating that SspB is a
specificity-enhancing factor for ClpXP that controls substrate choice (Levchenko, Seidel
et al., 2000). SspB and ClpX work together to recognize SsrA-tagged substrates
efficiently (Flynn, Levchenko et al., 2001).
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1.4

Objectives
The objective of this thesis was to develop a β-galactosidase assay to monitor the

degradation of Phd by ClpXP and to ascertain what factors affect that degradation. This
would improve our understanding of the regulation and control of the P1 plasmid
addiction system. Since Phd binds and neutralizes the toxin, Doc, it might be necessary
for Phd to be in this bound state to be degraded. Alternatively, Doc could act as a
protease inhibitor by protecting Phd when they are bound together. Both of these
possibilities were tested. Also, tests were performed to determine if the ClpXP
degradation of Phd requires any known accessory specificity factors utilized by other
ClpXP substrates. ClpXP was also tested to confirm that it was a required component of
the addiction phenomenon before any other experiments were performed.

	
  

27	
  

CHAPTER 2

MATERIALS AND METHODS

2.1

Media
Cells were grown in either Luria-Bertani (LB) broth or on LB agar (Fisher

Scientific). Plasmid selection was maintained by adding 100µg/mL
ampicillin (Amp) (Fisher Scientific), 20µg/mL chloramphenicol (Cm) (Fisher Scientific),
30µg/mL kanamycin (Kan) (Sigma Chemical), or 80µg/mL spectinomycin (Spec) (Fisher
Scientific) to the media. In order to identify colonies producing β-galactosidase, 20µg/ml
of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) (Fisher Scientific) was
added to the media. In order to induce the transcription of constructs utilizing the PBAD
promoter, 0.2% of L-(+)-Arabinose (ICN Biomedicals Inc) was added to the media.

2.2

Bacteria and Culture Techniques
All strains were derivatives of E. coli MC1061 (Casadaban and Cohen, 1980).

Bacterial strains were streaked on LB agar plates with the appropriate antibiotics added
and incubated overnight at 30°C. Cells were considered to be healthy if the colonies
grown were homogeneous in size and color with a smooth, shiny appearance. Cells were
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considered to be unhealthy if the colonies appeared small, heterogenous in size and color,
or had a rough surface.
Liquid cultures were prepared in 18 x 150mm glass test tubes by inoculating 5mL
of LB broth with the appropriate antibiotics added with cells picked from a single,
isolated colony. These cultures were incubated for 12-16 hours at 30°C in a roller drum
set at 30 revolutions per minute (rpm). Uninoculated media controls were always
included.
Freezer stocks were prepared by mixing 750µL of each overnight culture with
250µL of sterile 50% glycerol (Fisher Scientific) and storing at -80°C. Overnight
cultures were used to perform many experiments including plasmid purifications,
transformations, phage transductions, phage titers, addiction assays, and β-galactosidase
repression and degradation assays. Whenever necessary, overnight cell cultures were
pelleted in a Damon IEC Division HN-S centrifuge at approximately 3675 rpm or relative
centrifugal force (RCF) of 1926 x g. Bacterial strains and their descriptions are presented
in Table 2.1.

2.3

Construction of Strains for Addiction Assay

2.3.1

Phage Stock Prep
BR7203 containing the temperature-sensitive, high-transducing

P1 cl.100 dam rev-b phage was grown on LB agar and then in LB liquid culture to obtain
healthy cells. One hundred µL of the overnight culture were transferred into 5mL of
LB + 10mM CaCl2 and allowed to incubate at 30°C in the roller drum at 30 rpm for
3 hours. The sample was then transferred to a 42°C shaking water bath at 100 rpm
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Table 2.1
Strains
Strain
Initial strains:
NM409
(MC1061)
BR6486
BR6548

Description and Constructiona

Source

araD139, Δ(ara-leu)7696, ΔlacX74, galUgalK,
hsdR2(rk-mk+) mcrB1, rpsL (StrR)
λRDM11(P-phd(all)-lacZYA) into MC1061, placIq,
Kanr
F’lacIqZΔM15, Tn10 in MC1061, Tetr, for
α-complementation

(Casadaban and
Cohen, 1980)
Lab Collection
(Ireton, Rudner et al.,
1993)
(Magnuson, Lehnherr
et al., 1996)

NM210
(BR7025)
NM360
(BR7047)
NM169
(BR7052)
NM130
(BR7054)

λRDM12(Pr92::lacZYA) into MC1061,
pRDM068(pBAD24), Ampr
λRDM11(P-phd(all)-lacZYA) into MC1061,
pRDM073(pBAD-doc wt), Ampr
λRDM11(P-phd(all)-lacZYA) into MC1061,
pRDM075(pBAD-docH66Y), Ampr

BR7186

MC4100 Δlac, mal::lacIq

Gottesman, personal
communication

BR7187

clpP::cat into BR7186, Cmr

Lab Collection

BR7188

clpX::kan into BR7186, Kanr

Lab Collection

BR7203

Temperature sensitive P1 cl.100 dam rev-b in MC1061

placIq into BR7024, Kanr

NM020
pRS1551 into MC1061, Ampr
(XY229)
Intermediate strains:
NM011
clpX::kan(P1mertz10) into MC1061, Kanr
NM021
pNM001(Ptac-phd::lacZYA) into BR6548, Tetr
NM071
clpP::cat(P1mertz53) into NM029, Cmr
NM083
sspB::kan(P1mertz61-2) into MC1061, Kanr
NM086
rssB::Tn10(P1mertz62-1) into MC1061, Tetr
NM087
sspB::kan(P1mertz63-3) into NM086, Kanr, Tetr
NM215
clpP::cat(P1mertz71) into BR7025, Cmr, Kanr
NM246
placI into BR7024, Cmr
NM247
placI into NM065, Cmr, Kanr
NM248
placI into NM059, Cmr
NM249
placI into NM069, Cmr, Kanr

Lab Collection
Lab Collection
Lab Collection

Sternberg, personal
communication
Zhao, personal
communication
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

a. Ampr, Cmr, Kanr, Strr, and Tetr indicate resistance to ampicillin, chloramphenicol,
kanamycin, streptomycin, or tetracycline, respectively.
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Table 2.1 (continued)
Strains
Description and Constructiona

Strain

Source

Addiction Assay Strains:
NM018
NM019
NM088
NM089
NM090
NM091
NM092

pGB2ts into NM011, Kanr, Specr

This study

r

pGB2ts::phd-doc into NM011, Kan , Spec
r

pGB2ts into NM083, Kan , Spec

r

pGB2ts::phd-doc into NM083, Kan , Spec
pGB2ts into NM086, Kan , Spec

r

r

This study
This study

r

NM093
pGB2ts::phd-doc into NM087, Kan , Spec
NM239
pGB2ts into MC1061, Specr
(BR6567)
NM240
pGB2ts::phd-doc into MC1061, Specr
(BR6568)
β-galactosidase Degradation Assay Strains:
NM022

This study
This study

pGB2ts::phd-doc into NM086, Kan , Spec
pGB2ts into NM087, Kan , Spec

r

r

r

r

This study
This study

r

r

r

r

λmertz30(Ptac-phd::lacZYA) on MC1061, Tetr

This study
(Magnuson, Lehnherr
et al., 1996)
(Magnuson, Lehnherr
et al., 1996)
This study

NM064

clpX::kan(P1mertz54) into NM022, Kan

r

This study

NM077

clpP::cat(P1mertz52) into BR7024, Cmr

This study

r

NM100

pBAD-doc wt into NM022, Amp

NM105

pBAD-doc wt into NM064, Ampr, Kanr
r

NM133

pBAD24 into NM022, Amp

NM134

pBAD-docH66Y into NM022, Ampr
r

This study
This study
This study

r

NM135

pBAD24 into NM064, Amp , Kan

NM136

pBAD-docH66Y into NM064, Ampr, Kanr

β-galactosidase Repression Assay Strains:
NM034
pRDM034(Ptac-phd) into BR7025, Ampr, Kanr
(BR7028)
NM035
pKK223-3 into BR7025, Ampr, Kanr
(BR7030)
NM058
λRDM12(Pr92::lacZYA) into MC1061
(BR7024)
NM059
λRDM11(P-phd(all)-lacZYA) into MC1061
(BR6467)

This study
This study
This study
(Magnuson, Lehnherr
et al., 1996)
(Magnuson, Lehnherr
et al., 1996)
(Magnuson, Lehnherr
et al., 1996)
(Magnuson, Lehnherr
et al., 1996)

a. Ampr, Cmr, Kanr, Specr, and Tetr indicate resistance to ampicillin, chloramphenicol,
kanamycin, spectinomycin, or tetracycline, respectively.

	
  

31	
  

Table 2.1 (continued)
Strains
Strain

Description and Constructiona

Source

β-galactosidase Repression Assay Strains (continued):
NM065
clpX::kan(P1mertz35) into BR7024, Kanr
NM069
NM074
NM075
NM077
NM078
NM148
NM149
NM150
NM151
NM184
NM185
NM186

clpX::kan(P1mertz54) into NM059, Kan

r

r

This study

r

r

r

This study

clpP::cat(P1mertz52) into NM034, Amp , Cm , Kan
clpP::cat(P1mertz52) into NM035, Amp , Cm , Kan
clpP::cat(P1mertz52) into NM058, Cm

r

clpP::cat(P1mertz52) into NM059, Cm

r

This study

r

r

This study

r

r

This study

r

r

This study

clpX::kan(P1mertz64) into NM065, Cm , Kan
clpX::kan(P1mertz64) into NM069, Cm , Kan
clpP::cat(P1mertz65) into NM071, Cm , Kan
clpP::cat(P1mertz65) into NM078, Cm , Kan
pGB2ts into NM029, Spec

r

This study

pGB2ts::phd-doc into NM029, Spec

r

P1 Cm(P1mertz78) into NM029, Cm

NM203
NM207
(BR7055)
NM208
(BR7057)
NM221
NM223
NM224
NM225

P1 Cm(P1mertz78) into NM059, Cm
r

pGB2ts into NM065, Kan , Spec

This study

r

NM188

NM199

This study
r

r

NM198

This study

r

P1 Kan(P1mertz79) into NM029, Kan

NM197

This study

r

NM187
NM196

This study

r

This study
r

This study
This study

r

This study

r

pGB2ts::phd-doc into NM065, Kan , Spec
r

pGB2ts into NM071, Cm , Spec

r

This study

r

This study

r

pGB2ts::phd-doc into NM071, Cm , Spec
P1 Kan(P1mertz79) into NM059, Kan

r

This study

r

This study

pRDM076(pGB2) into BR7025, Kanr, Specr

Lab Collection

pRDM078(pGB2-Ptac-phd) into BR7025, Kanr, Specr

Lab Collection

pGB2-Ptac-phd-doc into NM210, Kanr, Specr

This study

r

r

pGB2 into NM215, Cm , Kan , Spec
r

r

r

pGB2-Ptac-phd into NM215, Cm , Kan , Spec
r

r

This study
r

pGB2-Ptac-phd-doc into NM215, Cm , Kan , Spec

This study
r

This study

a. Ampr, Cmr, Kanr, and Specr indicate resistance to ampicillin, chloramphenicol,
kanamycin, or spectinomycin, respectively.
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for 2 hours in order to induce the phage to replicate. Next, 3-4 drops of chloroform were
added to the sample and it was pelleted in a centrifuge at room temperature for
10 minutes. All phage were pelleted in a Damon IEC Division HN-S centrifuge at
approximately 3675 rpm or 1926 x g whenever necessary. The supernatant was
transferred to a capped glass tube and 3-4 drops of chloroform were added to finalize the
phage stock. These were stored at 4°C until needed. Phage descriptions are presented in
Table 2.2.
2.3.2

Phage Titer
Phage titers were performed on all phage stock preps in order to determine their

active phage concentrations. Wild-type (MC1061) cells were grown on LB agar and then
in LB + 10mM CaCl2 liquid culture. The overnight cell culture was pelleted in a
centrifuge at room temperature for 5 minutes. The supernatant was poured off and the
pellet was resuspended in 5mL of 10mM CaCl2. Ten-fold serial dilutions of the phage
stock were made in 13 x 100mm glass test tubes and mixed with the CaCl2 starved cells.
These were incubated at room temperature for 20 minutes to allow for phage adsorption.
A no-phage control was always included for each phage stock. Water soft agar (0.8%)
was heated in the microwave until fully melted. The water soft agar was placed in a
water bath to cool to 52°C before CaCl2 was added to a final concentration of 10mM.
Next, 3.5mL of the water soft agar were added to each phage/cell mixture and the
solution was gently vortexed and then immediately poured over LB plates. The plates
were incubated at room temperature for 20 minutes and then placed in either a 30°C or a
42°C (if the phage was temperature sensitive) incubator overnight. The number of phage
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Table 2.2
Phages
Phage

Description

Source

λRS45

lacZYA transcriptional fusion vector

(Simons, Houman et al.,
1987)

λRS468

lacZYA transcriptional fusion vector with more
N-terminal lacZ sequences than λRS45

Simons, personal
communication

λRDM11

Pr92 fused to the full coding sequence of Phd
followed by lacZYA in λRS45

(Magnuson and
Yarmolinsky, 1998)

λRDM12

Pr92 transcriptionally fused to lacZYA in
λRS45

(Magnuson, Lehnherr et
al., 1996)

λmertz30

Ptac-phd fused to lacZYA

This study; recombinant
of λRS468 and pNM001

P1 c1.100
dam rev-b

High transducer

Sternberg, personal
communication

plaques formed within the water soft agar was recorded. To determine the number of
phage particles per mL, the following formula was utilized:
phage/mL = (number plaques/plate) x (1/volume plated) x dilution factor
2.3.3

Phage Lysate Production
In order to take advantage of the fact that P1 can be used as a transducing particle,

phage lysates containing the genetic marker of interest were produced. Bacterial strains
containing the selectable genetic markers of interest, particularly clpP::cat, clpX::kan,
sspB::kan, rssB::Tn10, were grown on LB agar and in LB + 10mM CaCl2 liquid culture.
Then, 50µL of the high transducing P1 phage stock were mixed with 50µL of each
genetic marker and incubated for 2 hours at 30°C in 5mL LB broth + 10mM CaCl2 in the
30 rpm roller drum. The samples were then transferred to a 42°C shaking water bath at
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100 rpm for 1 hour. Next, 3-4 drops of chloroform were added to the sample and it was
pelleted in a centrifuge at room temperature for 10 minutes. The supernatant was
transferred to a capped glass tube and 3-4 drops of chloroform were added to finalize the
phage lysate. These were stored at 4°C until needed.
2.3.4

Transduction
Phage lysates containing a genetic marker of interest can be transduced into a

bacterial strain. Wild-type (MC1061) cells were grown on LB agar and then in
LB + 10mM CaCl2 liquid culture to obtain healthy cells. The next day, 100µL of cells
were mixed with 100µl, 10µl, or 1µl of the phage lysate containing the genetic marker of
interest and then they were brought up to a final volume of 200µL with LB
broth + 10mM CaCl2. This solution was incubated at 30°C for 30 minutes. Then, 100µL
of 1M Sodium (Na) Citrate were added to the tubes, they were vortexed, and incubated at
30°C for 15 minutes. Finally, 100µL of each tube were spread onto LB agar plates
containing the appropriate antibiotic to select for the desired genetic marker. No-phage
controls were included. The plates were allowed to sit at room temperature for
approximately ten minutes in order to allow the solution to absorb into the agar. They
were incubated at 30°C overnight. As long as the no-phage controls showed no growth,
the plates with transductants were determined to have been transduced successfully. The
transductants were colony purified three times by plating on LB agar plates with the
appropriate antibiotic and incubating overnight at 30°C. After the third purification, one
well-isolated colony was grown overnight in liquid culture and a freezer stock was made.
This new strain was stored at -80°C until needed.
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2.3.5

Isolation of Plasmid DNA
Plasmid DNA was isolated using the Qiagen QIAprep Spin Miniprep Kit. Strains

containing the plasmids of interest were grown on LB agar and then in LB liquid culture
with the appropriate antibiotics. The overnight liquid culture was pelleted in a centrifuge
at room temperature for 10 minutes. The supernatant was poured off and the pellet was
resuspended in 250µL of ice-cold P1 buffer. The solution was transferred to a sterile
1.5mL microcentrifuge tube and 250µL of P2 buffer were added to the solution. The tube
was inverted 4-6 times and 350µL of N3 buffer were added to the tube and it was once
again inverted 4-6 times. The solution was centrifuged at room temperature for
10 minutes at 13,000 rpm (15700 x g). All microcentrifuge tubes were centrifuged in an
Eppendorf 5415D centrifuge, whenever necessary. The supernatant was then applied to a
QIAprep spin column and centrifuged at room temperature for one minute at 13,000 rpm.
The flow-through was discarded and 500µL of PB buffer were added. It was centrifuged
at room temperature for one minute at 13,000 rpm. The flow-through was discarded and
750µL of PE buffer were added. It was centrifuged at room temperature for one minute at
13,000 rpm. The flow-through was discarded and it was centrifuged again at room
temperature for one minute at 13,000 rpm. The QIAprep spin column was then placed in
a sterile 1.5mL microcentrifuge tube. The plasmid was eluted by adding 50µL of EB
buffer to the center of the QIAprep spin column and allowing it to absorb into the
membrane for one minute. It was centrifuged at room temperature for one minute at
13,000 rpm. Plasmids were stored at 4°C until needed. Plasmid descriptions are
presented in Table 2.3.
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Table 2.3
Plasmids
Plasmid
pKK223-3
pGB2 (pRDM076)

Vectora

Insert
DNA

Primers
Usedb

Ptac expression vector,
pMB1 ori, Ampr
Modest copy number
cloning vector, pSC101 ori,
Specr

Source
(Brosius and Holy, 1984)
(Churchward, Belin et al.,
1984)

pGB2-Ptac-phd
(pRDM078)

pGB2 & pKK223-3

Phd

Lab Collection

pGB2-Ptac-phd-doc
(pRDM079)

pGB2 & pKK223-3

Phd and
Doc

Lab Collection

pGB2ts
pGB2ts::phddoc

pGB2 deriviative whose
replication is temperature
sensitive, Specr
pGB2 deriviative whose
replication is temperature
sensitive, Specr

(Clerget, 1991)
Phd and
Doc

(Lehnherr and
Yarmolinsky, 1995)

placIq

pACYC177, p15A ori, Kanr

lacIq

(Magnuson, Lehnherr et
al., 1996)

placI

p15A ori, CMr

lacI

Novagen

Ptac-phd
(pRDM034)

pKK223-3, Ampr

Phd

(Magnuson, Lehnherr et
al., 1996)

Ptac-doc
(pRDM037)

pKK223-3, Ampr

Doc

Lab Collection

Ptac-docH66Y
(pRDM067)

pKK223-3, Ampr

DocH66Y

Lab Collection

pRS1551

lacZ translational fusion
vector, pMB1 ori, Ampr

Simons, personal
communication

pBAD24
(pRDM068)

pBAD expression vector,
pBR ori, Ampr

(Guzman, Belin et al.,
1995)

pBAD-doc wt
(pRDM073)

pBAD24, Ampr

Doc

(Magnuson and
Yarmolinsky, 1998)

pBAD-docH66Y
(pRDM075)

pBAD24, Ampr

DocH66Y

(Magnuson and
Yarmolinsky, 1998)

pNM001

pRS1551, Ampr

Ptac-phd

NEM001
&
NEM004

This study

a. Ampr, CMr, Kanr, and Specr indicate the vectors carry the genes of resistance to
ampicillin, chloramphenicol, kanamycin, or spectinomycin, respectively.
b. See Table 2.4 for primer sequences
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2.3.6

Transformation
Strains made from the previous transduction experiment were grown on LB agar

and then in LB liquid culture, supplemented with the appropriate antibiotics. One
hundred µL of the overnight culture were transferred to a fresh 5mL tube of LB broth
supplemented with the appropriate antibiotics and incubated for 3 hours at 30°C in the
30 rpm roller drum. This allowed the cells to reach a state of logarithmic growth.
These cultures were pelleted in a centrifuge for 5 minutes at room temperature.
The supernatant was poured off and the pellet was resuspended in 1mL of ice cold 1M
CaCl2. The samples were stored on ice for 20 minutes and then transferred to sterile
1.5mL microcentrifuge tubes. The samples were centrifuged at room temperature for
5 minutes at 13,000rpm. The supernatant was aspirated and the pellet was resuspended in
500µL of ice cold 1M CaCl2 in order to obtain competent cells for transformation. Then,
3µL of plasmid DNA containing the insert of interest were mixed with 50µL of
competent cells and this was stored on ice for 20 minutes. No-plasmid controls were also
included.
The samples were incubated at 42°C for 90 seconds and then placed back on ice
for 2 minutes. Five volumes of LB broth were added to the samples and they were
incubated at 30°C for 40 minutes. Finally, 100µL of each sample were spread on LB
agar plates supplemented with the appropriate antibiotics. The plates were incubated at
room temperature for approximately 10 minutes in order to allow the solution to absorb
into the agar. They were incubated at 30°C overnight. As long as the no-plasmid
controls showed no growth, the plates with transformants were considered to be
successfully transformed. The transformants were colony purified two times by plating
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on LB agar plates with the appropriate antibiotic and incubating overnight at 30°C. After
the second purification, one well-isolated colony was grown overnight in liquid culture
and a freezer stock was made. This new strain was stored at -80°C until needed.
All of the strains constructed for the addiction assay are listed in Table 2.1.

2.4

Construction of Strains for β-galactosidase Degradation/Repression Assays

2.4.1

Primer Design
Primers were designed to generate the insert of interest. The forward primer from

5’ to 3’, NEM001, started at a SmaI restriction site and was immediately followed by the
downstream sequence of pRDM034 (Ptac-phd). The reverse primer from 3’ to 5’,
NEM004, started at a BamHI restriction site and was immediately followed by the
reverse complement of the end of Phd’s coding sequence. The primers were made by
MWG Biotech. The sequences of the primers are shown in Table 2.4.

Table 2.4
Primers
Code
NEM001
NEM004

Descriptiona
Forward phd
Reverse phd

Sequence (5’ 3’)
5’ tcc ccg ggg gag ctt atc gac tgc acg 3’
5’ ggg gat ccc ctc ggt taa cca gtt cct tg 3’

# Bases
27
29

a. Forward: forward primer for constructs; Reverse: reverse primer for constructs
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2.4.2

Polymerase Chain Reaction (PCR)
The pRDM034 (Ptac-phd) plasmid was isolated as described in section 2.3.5 and

was used as the template for PCR. One µL of the template, 1µL of NEM001 primer, and
1µL of NEM004 primer were mixed with 0.5µL of Taq polymerase \ (Promega) and
21.5µL of sterile diH2O for a total reaction volume of 25µL. The thermal cycler program
used is shown in Table 2.5. Primer-encoded SmaI and BamHI restriction sites flanked
the PCR fragments. The PCR fragments were run on 2% high-melt agarose gel with a
PhiX174 DNA-HaeIII digest marker (New England Biolabs, NEB) for size confirmation.

Table 2.5
Thermal Cycler Program
Temperature (°C)
95

Duration
3 minutes

95

1 minute

52

1 minute

72

1 minute

95

1 minute

70

1 minute

72

2 minutes

72
4

5 minutes
∞

2.4.3

# of cycles
1
5

25

1

Purification of PCR Products
The PCR products were purified using a phenol:chloroform extraction procedure

followed by an ethanol precipitation procedure. DNA was extracted from the PCR
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products by adding 1 volume of 5M ammonium acetate to a 1.5mL microcentrifuge tube
containing the PCR product and vortexing. Then, 1/100 volume of 1M MgCl2 was added
followed by the addition of volume of a 25 phenol:24 chloroform:1 isoamyl alcohol
mixture. The sample was vortexed until an emulsion formed and then it was centrifuged
at room temperature for 2 minutes at 12,000 rpm (13,400 x g). The supernatant was
transferred to a sterile 1.5mL microcentrifuge tube. One volume of a
24 chloroform:1 isoamyl alcohol mixture was added and the sample was vortexed again.
It was then centrifuged at room temperature for 2 minutes at 12,000 rpm. The
supernatant was transferred to a sterile 1.5mL microcentrifuge tube to complete the
extraction procedure.
During the precipitation procedure, the sample was stored on ice unless otherwise
stated. To precipitate the DNA, two volumes of ice-cold 100% ethanol and 1/100 volume
of 1mg/mL glycogen were added to the extracted sample and it was vortexed. The
sample was stored at -20°C for 30 minutes and then centrifuged at 4°C for 20 minutes at
12,000 rpm. The supernatant was removed and discarded, then replaced with an equal
volume of ice-cold 70% ethanol to resuspend the pellet. The sample was centrifuged at
4°C for 20 minutes at 12,000 rpm. The supernatant was gently aspirated and the pellet
was allowed to air-dry for 15 minutes at room temperature. The pellet was resuspended
in Tris-EDTA (TE) pH 8.0 buffer using the same volume as the initial start volume. The
precipitated DNA sample was run on 2% high-melt agarose gel with a
PhiX174 DNA-HaeIII digest marker for size confirmation. The precipitated DNA was
stored at 4°C until needed.
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2.4.4

Restriction Digest of Precipitated PCR products
The precipitated PCR products were digested utilizing a sequential restriction

digest procedure where 20µL of the purified product were mixed with 14µL of sterile
diH2O, and 4µL of NE Buffer #4 (NEB) in a 0.5µl microcentrifuge tube. Then, 2µL of
SmaI restriction enzyme (NEB) were added to the tube and the solution was mixed by
flicking the tube. This was incubated at 25°C for 2 hours then inactivated by incubation
at 65°C for 20 minutes. Then, 0.9µL of 5M NaCl and 2.1µL of bovine serum
albumin (BSA) (NEB) were added to the tube and the solution was mixed gently.
Two µL of BamHI restriction enzyme (NEB) were added to the tube and the solution was
mixed by flicking the tube. This was incubated at 37°C for 2 hours then inactivated by
incubation at 80°C for 20 minutes. The digested insert was stored at 4°C until needed.
2.4.5

Ligation of Insert and Vector
The vector used to construct these strains was the pRS1551 cloning vector.

NM020 was grown on LB agar and then in LB liquid culture supplemented with Amp.
The plasmid DNA was isolated as described in section 2.3.5. The vector DNA was then
purified as described in section 2.4.3. Finally, the vector was digested as described in
section 2.4.4. The digested insert and vector samples were purified on 1% low-melt
agarose gel (NEB) and 3% NuSieve GTG agarose gel (BioWittaker Molecular
Applications), respectively. The PhiX174 DNA-HaeIII digest marker and the
λDNA-HindIII digest marker (Promega) were used to verify the size of insert and vector,
respectively. Both DNA fragments were trimmed from their gels and mixed together by
performing an in-gel ligation procedure.
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The DNA fragments cut out of the agarose gel were melted separately at 65°C. A
ligation mixture was made containing 7µL of sterile diH2O, 2µL of 10x T4 DNA ligase
buffer (NEB) and 1µL of T4 DNA ligase (NEB). Ten µL of the ligation mixture were
mixed with 8.5µL of melted vector and 1.5µL of melted insert. This solution was mixed
by pipetting and incubated on ice for 10 minutes. The sample was incubated overnight at
20°C and stored at 4°C until needed.
2.4.6

Transformation of PCR-plasmid Clones
A transformation procedure was performed as described in section 2.3.6 with the

following exceptions. Competent cells were made from strain BR6548. Instead of
adding plasmid DNA to the competent cells, the previously described ligation product
was added. The samples were plated on LB Amp X-gal plates and only transformants
that produced blue colonies were selected for colony purification.
The transcriptional lacZ fusion vector of pRS1551, which only contains the
beginning codons for the lacZ gene, and the Ptac-phd promoter were fused to the lacZ
gene. pRS1551 derivatives encode the LacZ α-peptide. Strain BR6548 produces the
LacZ protein with the 11th through 41st amino acids deleted. So, when the
pRS1551 derivatives were transformed into this strain, α-complementation restored
β-galactosidase activity and resulted in blue colonies. This generated a
pRS1551 derivative designated pNM001. The new strain containing pNM001 was
colony purified and named NM021.
2.4.7

DNA Sequencing
In order to verify that pNM001 was properly constructed, it was isolated from

NM021 as described in section 2.3.5. The plasmid was digested by mixing 10µL of the
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purified plasmid with 6µL of sterile diH2O, and 2µL of NE Buffer #2 (NEB) in a 0.5µl
microcentrifuge tube. This solution was mixed gently. Then, 1µL of each of HincII
restriction enzyme (NEB) and BamHI restriction enzyme were added to the tube and it
was mixed by flicking the tube. This was incubated at 37°C for 2 hours and inactivated
by incubation at 80°C for 20 minutes.
Quantification of the digested DNA was performed on 1% low-melt agarose
gel (NEB) and confirmed to be the correct size by the λDNA-HindIII digest
marker (Promega). A 25µl sample of the pNM001 plasmid was sent to MWG Biotech
and dideoxynucleotide sequencing confirmed that the plasmid was constructed properly.
2.4.8

Translational lacZ Fusion to the Chromosome
A lab collection phage stock of λRS468 was used to perform a phage infection on

strain NM021 containing the pNM001 plasmid. NM021 was grown on LB Tetracycline
(Tet) agar and in LB liquid media supplemented with 10µg/mL Tet and 10mM
MgSO4. The overnight cell culture was pelleted in a centrifuge at room temperature for
10 minutes. The supernatant was poured off and the pellet was resuspended in 2.5mL of
10mM MgSO4. The cell suspension was incubated for 1 hour in a 30 rpm roller drum at
30°C. One hundred µL of the cell suspension were mixed with 10µL of the
λRS468 phage stock, vortexed briefly, and incubated for 20 minutes at room temperature.
The tube was then placed in a 30 rpm roller drum at 30°C until noticeable clearing was
observed. Three to four drops of chloroform were added to the sample and it was
pelleted in a centrifuge at room temperature for 10 minutes. The supernatant was
transferred into a capped glass tube and 3-4 drops of chloroform were added. This
sample was titered as described in section 2.3.2 using NM021 cells and LB X-gal plates.
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Recombinant phage were indicated by the formation of blue plaques during the
phage titer procedure. A Pasteur pipet was used to pick up a blue plaque and it was
transferred to a tube containing 100µL of MgSO4 starved BR6548 cells. This was
incubated at room temperature for 20 minutes. Five mL of LB + 10mM MgSO4 were
added to the tube and it was incubated for 4 hours in a 30 roll per minute roller drum at
30°C. Then, 3-4 drops of chloroform were added to the sample and it was pelleted in a
centrifuge at room temperature for 10 minutes. The supernatant was transferred into a
capped glass tube and 3-4 drops of chloroform were added to finalize this phage lysate,
which was designated as λmertz30.
The λmertz30 phage lysate was titered as described in section 2.3.2 using
BR6548 cells and LB X-gal plates. A sterile inoculating needle was used to stab into the
center of a well-isolated blue plaque to select a lysogen containing the fused lacZ gene.
The lysogen was streaked out on an LB X-gal plate and grown overnight at 30°C. A
well-isolated blue colony was restreaked on LB X-gal and colony purified as previously
described. This new strain was named NM022.
2.4.9

Final Steps in Strain Construction
To construct the final strains that would be used in the degradation/repression

assays, clpX::kan from P1mertz54 or clpP::cat from P1mertz53 was transduced into
NM022 using the transduction procedure described in section 2.3.4. These new strains
were colony purified and named NM064 and NM070, respectively. In some cases,
clpX::kan, clpP::cat, P1 Cm, or P1 Kan was transduced into strains containing a λ phage
encoding the natural Phd/Doc promoter, Pr92, fused to the lacZYA genes (λRDM12) or a
λ phage encoding Pr92 fused to the full coding sequence of phd followed by
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lacZYA (λRDM11). In some cases, plasmids were also transformed, as described in
section 2.3.6, into strains containing the various λ phages.
All of the strains constructed for the β-galactosidase Degradation/Repression
Assays are listed in Table 2.1.

2.5

Addiction Assays
To perform an addiction assay, the strains listed in Table 2.1 under Addiction

Assay strains, were grown on LB Spec agar and in LB liquid culture supplemented with
Spec. A series of ten-fold dilutions of the overnight cultures was made in 13 x 100mm
glass test tubes using 0.85% saline. One hundred µL aliquots of these dilutions were
spread on two plates each of LB agar. One set of plates was incubated at 30°C to allow
replication of the plasmid to continue. The other set of plates was incubated at 42°C to
force loss of the plasmid. In order to confirm plasmid loss, colonies that grew on the
plates incubated at 42°C were restreaked on LB Spec agar and incubated at 30°C. When
colonies on both sets of plates were large enough to visualize (~ 24 hours), the plates
were examined and those that contained between 20 and 200 colonies were counted.
Multiplying the number of colonies counted by the dilution factor resulted in the number
of colony forming units (CFU) that were in the original overnight culture. The efficiency
of plating (EOP) was also calculated by the dividing the number of CFU on the plates
incubated at 42°C by the number of CFU on the plates incubated at 30°C.
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2.6

β-galactosidase Degradation/Repression Assays
The β-galactosidase degradation/repression assays were based on the method of

Miller (Miller, 1992). Strains to be tested were grown on LB agar and then inoculated in
5mL of LB broth. LB media was supplemented with the appropriate antibiotics. To
ensure steady-state growth of all strains, the inoculation was vortexed and ten-fold serial
dilutions were made. All tubes were incubated for 12-16 hours in a 30 rpm roller drum at
30°C. The next day, the dilution of each strain that appeared to be in logarithmic growth
was selected and a 1mL aliquot was measured for its absorbance at 600nm (OD600). This
value was used to determine the amount of overnight culture added to a 125mL
Erlenmeyer flask containing 25,000µL of LB broth to achieve a starting OD600 of
0.005. The formula used to determine this was based on:
C1V1=C2V2
where:

C1 = OD600 of the measured sample
V1 = the volume (µl1) of the overnight culture to add to the flask contents
C2 = the desired starting OD600 (0.005)
V2 = the volume (25,000µl) of the flask contents

The rearranged formula was as follows:
(µl1) = (0.005)(25,000µl)
(OD600 of measured sample)
Once the proper amount of overnight culture was added to each flask, they were
placed into a shaker water bath at 30°C or 42°C and 160 rpm. The flasks were incubated
while shaking until the OD600 was measured to be between 0.05 and 0.5. The OD600 was
then measured every 30 minutes until 4 samples were collected. Then, 400µL of each
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sample were placed into a 2mL microcentrifuge tube and placed on ice. Next, 10µL of
toluene were added to each sample and they were vortexed for 20 seconds and either
placed back on ice or stored at -20°C.
The cells were incubated at 30°C for 5 minutes before 800µL of Z-buffer (0.06M
Na2HPO47H2O, 0.04M NaH2PO4H2O, 0.01M KCl, and 0.001M MgSO47H2O per L)
(Fisher Scientific) supplemented with 2.7mL/L of β-mercaptoethanol (BME) (Fisher
Scientific) and 1mg/mL ortho-nitrophenyl-β-D-galactopyranoside (ONPG) (Amresco).
This was recorded as the start time of the reaction. The tubes were incubated until a
yellow color developed indicating the β-galactosidase protein was being expressed. The
yellow color is produced due to the cleavage of ONPG to o-nitrophenol (Figure 2.1 and
Figure 2.2). Once the yellow color developed, the reaction was quenched by adding
500µL of 1M Na2CO3 (Fisher Scientific) and this was recorded as the stop time of the
reaction. The tubes were vortexed and placed on ice. They were centrifuged at room
temperature for 5 minutes at 13,000 rpm. The absorbance at 420nm (OD420) was
measured and the β-galactosidase specific activity (SA) was calculated using the
following equation:

	
  

48	
  

Figure 2.1: β-galactosidase Degradation Assay
β-galactosidase degradation assays were performed according to the method described by
Miller (Miller, 1992). Ptac-phd was fused to the front portion of the lacZ gene, which
encodes β-galactosidase. The β-galactosidase enzyme catalyzes the hydrolysis of the
reaction substrate ortho-nitrophenyl-β-D-galactopyranoside (ONPG) to
o-nitrophenol (ONP), which is a yellow compound. The absorbance of the reaction
mixture can be measured at 420nm and the intensity of the yellow color indicates the
amount of β-galactosidase expressed which, since it is fused to Phd, also indicates the
amount of Phd expressed. If the ClpXP protease is degrading Phd and subsequently
β-galactosidase, then there should be less Phd in strains containing ClpXP compared to
strains that contain a protease mutant. Therefore, strains containing the ClpXP protease
should be less yellow than strains with a protease mutant.
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Figure 2.2: β-galactosidase Repression Assay
Β-galactosidase assays were performed according to the method described by Miller
(Miller, 1992). The P1 plasmid addiction operon’s wildtype promoter or the promoter
and Phd are fused to the front portion of the lacZ gene, which encodes β-galactosidase.
The β-galactosidase enzyme catalyzes the hydrolysis of the reaction substrate
ortho-nitrophenyl-β-D-galactopyranoside (ONPG) to o-nitrophenol, which is a yellow
compound. When the promoter is turned on a vivid yellow color is produced. Binding of
Phd or of the Phd-Doc repressive complex to the promoter turns it off and a clear to
slightly yellow color is produced. The absorbance of the reaction mixture can be
measured at 420nm and the intensity of the yellow color indicates the amount of βgalactosidase expressed and the level of transcriptional repression of the lacZ gene by
Phd or the Phd-Doc repressive complex. If degradation of Phd is occurring by the ClpXP
protease then there should be less Phd to repress the promoter in those strains compared
to strains that are Clp-. Therefore, strains containing the ClpXP protease should be more
yellow than strains without the ClpXP protease.
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CHAPTER 3
RESULTS AND DISCUSSION

3.1

ClpXP is a Necessary Factor in the Mechanism of P1 Plasmid Addiction
In a wild-type E. coli strain, inclusion of a plasmid with thermosensitive

replication allows plasmid loss to be forced by a shift to nonpermissive temperatures.
Insertion on the plasmid of a TA system such as Phd-Doc thus allows detection of the
addictive phenotype, and the ability to assay mutants for their ability to disrupt
addiction (Lehnherr, Maguin et al., 1993).
In the three experiments shown in Table 3.1, two plasmids were utilized for this
addiction assay. The vector control, pGB2ts, has a temperature-sensitive mechanism of
replication and a spectinomycin resistant marker, but no TA system. The second plasmid
utilized was pGB2ts::phd-doc which is a derivative of pGB2ts that contains the P1
addiction module; Phd and Doc under the control of their own promoter (Lehnherr and
Yarmolinsky, 1995).
Table 3.1 displays the results of the addiction assay on the vector which
demonstrated that it was not addictive in a wild-type background since its efficiency of
plating was approximately one, indicating that the cells were growing normally at both
30°C and 42°C. The results of the addiction assay on the strain containing the addiction
module confirmed that it is addictive in a wild-type background since its efficiency of
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Table 3.1
Addiction Assay of ClpXP

Strain

Description
Plasmid

NM239

pGB2ts

NM018

pGB2ts

NM240

pGB2ts::
phd-doc

NM019

pGB2ts::
phd-doc

Chromosomal
Marker

clpX::kan

clpX::kan

Exp
#
1
2
3
1
2
3
1
2
3
1
2
3

CFU/mLa
42°C

30°C
8

70 x 10
94 x 108
74 x 108
49 x 108
56 x 108
58 x 108
18 x 107
10 x 106
38 x 107
47 x 108
68 x 108
49 x 108

64 x 108
89 x 108
88 x 108
49 x 108
87 x 108
46 x 108
120 x 108
64 x 108
84 x 108
31 x 108
53 x 108
52 x 108

EOPb
1.094
1.056
0.841
1.000
0.644
1.261
0.015
0.002
0.045
1.516
1.283
0.942

Resultsc
Not
Addictive
Not
Addictive
Addictive
Not
Addictive

a. CFU/mL refers to colony forming units per milliliter
b. EOP refers to Efficiency of Plating – this was determined by dividing the CFU/mL at
42°C by CFU/mL at 30°C
c. Addiction was known to occur when constructs containing pGB2ts::phd-doc approached
zero
d. Kan refers to kanamycin resistance

plating was approximately zero. These results established both a negative control and a
positive control for addiction. This allowed a comparison to a specific gene mutation
utilizing the knockout mutant, clpX::kan. Since proteolysis is needed in order to achieve
the addictive response, mutations that interfere with proteolysis should relieve addiction.
The P1 antitoxin protein, Phd, has been identified as a substrate for degradation by the
ClpXP protease (Lehnherr and Yarmolinsky, 1995). Performing the addiction assay on
strains carrying a mutation in the ClpXP protease gene should establish that the ClpXP
protease is a necessary factor in the mechanism of the P1 addiction system. A mutation
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in clpX did relieve addiction as expected and confirmed that clpX is needed for the
proteolysis of Phd. This construct thus provided another negative control for use in
future addiction assays.

3.2

The Phd-LacZ Fusion is Not Degraded at 42°C
Previous studies indicated that ClpXP was able to degrade a substrate when it was

fused to lacZYA (Schweder, Lee et al., 1996). In the λmertz30 strain, Ptac-phd is fused to
lacZYA; therefore the levels of expression of each should be identical. By performing a
β-galactosidase assay on strains containing this fusion, the amount of Phd expressed can
be ascertained by measuring the amount of β-galactosidase expressed. When ClpXP is
present in the cell, it should be degrading Phd. Therefore, there should be less Phd in
strains where ClpXP is present compared to strains where one of the ClpXP components
is absent. The specific activity of the strain containing the λmertz30 fusion and ClpXP
should be lower than the specific activity of strains containing this fusion and either of
the knockout mutants, clpX::kan or clpP::cat. Thus, the β-galactosidase assay can be
used as a degradation assay for strains containing the λmertz30 background. The strains
used for this β-galactosidase degradation assay are shown in Table 3.2.
The results of the β-galactosidase degradation assay performed at 42°C described
in section 2.6 show that there is no significant difference between strains with and
without ClpXP, as seen in Table 3.3 and Figure 3.1. These results were not expected and
indicate that measurable degradation is not occurring at 42°C. A β-galactosidase
degradation assay using these same strains was performed at 30°C to determine if
temperature was a factor in the degradation of Phd by ClpXP.
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Table 3.2
Strains used in β-galactosidase Degradation Assays in Section 3.2 and 3.3
The lac repressor was provided in all cases by F’lacIQZΔM15

Strain

LacZ/Phd source

ClpXP Phenotype

NM022

λmertz30(Ptac-phd::lacZYA)

ClpXP+

NM064

λmertz30(Ptac-phd::lacZYA)

ClpX-

NM070

λmertz30(Ptac-phd::lacZYA)

ClpP-

Table 3.3
β-galactosidase Degradation Assay of λmertz30(Ptac-phd::lacZYA) at 42°C
Degradation was said to be occurring if the mean specific activity increased in strains
containing a protease mutant. There was no significant difference between these strains.

	
  

Strain

Protease Phenotype

Mean Specific Activity

Standard Deviation

NM022

ClpXP+

47.09

10.11

NM064

ClpX-

53.32

2.38

NM070

ClpP-

38.15

10.8
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Degradation of the Phd-LacZ fusion at 42°C
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Figure 3.1: Specific Activity of λmertz30(Ptac-phd::lacZYA) with and without ClpXP
at 42°C
The Phd-LacZ fusion is not degraded at 42°C. If degradation was seen at this
temperature, the specific activity of the wild type strain would be less than the specific
activity seen in the mutant strains. There was no significant difference between the wild
type strain and the mutants indicating that degradation was not taking place.
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3.3

The Phd-LacZ Fusion is Not Degraded at 30°C
In order to determine if temperature was a factor in the degradation of Phd by

ClpXP, four repetitions using the strains presented in Table 3.2 were performed. The
results of these β-galactosidase degradation assays carried out at 30°C show that there
was no significant difference between strains with and without ClpXP in any of the trials,
as seen in Table 3.4 and Figure 3.2. These results indicate that measurable degradation
was not occurring at 30°C either. A change in temperature did not induce degradation.
These results could indicate that Doc, the toxin protein of the P1 plasmid addiction
operon, might be required in order for degradation of Phd by ClpXP to occur so this was
examined next.
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Table 3.4
β-galactosidase Degradation Assay of λmertz30(Ptac-phd::lacZYA) at 30°C
Degradation was said to be occurring if the mean specific activity increased in strains
containing a protease mutant. There was no significant difference between these strains.

Trial #

1

2

3

4

	
  

Strain

Protease Phenotype

Mean Specific
Activity

Standard
Deviation

NM022

ClpXP+

78.9

5.92

NM064

ClpX-

56.02

16.09

NM070

ClpP-

71.96

4.45

NM022

ClpXP+

75.53

7.85

NM064

ClpX-

67.5

2.27

NM070

ClpP-

68.37

4.12

NM022

ClpXP+

73.75

3.47

NM064

ClpX-

64.45

6.92

NM070

ClpP-

71.23

4.18

NM022

ClpXP+

59.08

4.45

NM064

ClpX-

71.46

5.28

NM070

ClpP-

52.52

5.94

57	
  

Mean Specific Activity (Miller Units)

Degradation of the Phd-LacZ fusion at 30°C
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Figure 3.2: Specific Activity of λmertz30(Ptac-phd::lacZYA) at 30°C
The Phd-lacZ fusion is not degraded at 30°C. If degradation was seen at this
temperature, the specific activity of the wild type strain would be less than the specific
activity seen in the mutant strains. There was no significant difference in any of the four
trials between the wild type strain and the mutants indicating that degradation was not
taking place.

3.4

Doc is Not Required for Degradation in the λmertz30(Ptac-phd::lacZYA)
Background
It might be necessary for Doc to be present in order for ClpXP to recognize and/or

degrade Phd. To test this theory, the strains listed in Table 3.5 were utilized. Three
repetitions of the β-galactosidase degradation assays were performed at 30°C. Arabinose
was added during the third repetition in case it was needed to induce the PBAD promoter.
The results of the β-galactosidase degradation assay performed at 30°C with and
without arabinose showed that there was no significant difference between strains with

	
  

58	
  

Table 3.5
Strains used in β-galactosidase Degradation Assay in Section 3.4
The lac repressor was provided in all cases by F’lacIQZΔM15

Strain

LacZ/Phd Source

Doc source
(or vector)

ClpXP Phenotype

NM133

λmertz30(Ptac-phd::lacZYA)

pBAD24 (vector)

ClpXP+

NM135

λmertz30(Ptac-phd::lacZYA)

pBAD24 (vector)

ClpX-

NM100

λmertz30(Ptac-phd::lacZYA)

pBAD-doc wt

ClpXP+

NM105

λmertz30(Ptac-phd::lacZYA)

pBAD-doc wt

ClpX-

NM134

λmertz30(Ptac-phd::lacZYA)

pBAD-docH66Y

ClpXP+

NM136

λmertz30(Ptac-phd::lacZYA)

pBAD-docH66Y

ClpX-

and without ClpXP, as seen in Table 3.6, Figure 3.3, and Figure 3.4. These results
indicated that Doc was not needed for the ClpXP degradation of Phd or that Doc does not
interfere with the ClpXP degradation of Phd. Although, it also must be considered that in
these particular strains Doc is in trans when compared to Phd and it could be necessary
for Doc to be in cis as compared to Phd in order to impart any degradation influences.
One other possibility is that the λmertz30(Ptac-phd::lacZYA) fusion is not degraded by
ClpXP.
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Table 3.6
β-galactosidase Degradation Assay of λmertz30(Ptac-phd::lacZYA) with Doc at 30°C
Degradation was said to be occurring if the mean specific activity increased in strains
containing a protease mutant. There was no significant differnce between these strains

Trial
#

Strain

Protease
Phenotype

Contents

Mean
Specific
Activity

Standard
Deviation

These strains were grown without Arabinose

1

NM133 pBAD24 (pBAD vector)

ClpXP+

194.02

39.5

NM135 pBAD24 (pBAD vector)

ClpX-

228.4

32.72

NM100

pBAD-doc wt

ClpXP+

231.64

17.97

NM105

pBAD-doc wt

ClpX-

194.57

43.44

NM134

pBAD-docH66Y

ClpXP+

213.32

22.26

NM136

pBAD-docH66Y

ClpX-

218.15

58.49

These strains were grown without Arabinose

2

NM133 pBAD24 (pBAD vector)

ClpXP+

237.87

53.53

NM135 pBAD24 (pBAD vector)

ClpX-

221.81

46.47

NM100

pBAD-doc wt

ClpXP+

313.4

38.25

NM105

pBAD-doc wt

ClpX-

203.59

31.87

These strains were grown with Arabinose

3

	
  

NM133 pBAD24 (pBAD vector)

ClpXP+

448.79

29.17

NM135 pBAD24 (pBAD vector)

ClpX-

422.17

81.55

NM100

pBAD-doc wt

ClpXP+

413.06

55.1

NM105

pBAD-doc wt

ClpX-

451.9

71.67
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Figure 3.3: Specific Activity of λmertz30(Ptac-phd::lacZYA) with Doc at 30°C
The Phd-LacZ fusion with Doc is not degraded at 30°C. If degradation required the
presence of Doc and was seen at this temperature, the specific activity of the wild type
strains containing ClpXP would be less than the specific activity seen in the strains
containing a ClpXP mutant. There was no significant difference between the wild type
strains and the mutants indicating that degradation was not taking place.
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Degradation of the Phd-LacZ fusion with Doc at 30°C
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Figure 3.4: Specific Activity of λmertz30(Ptac-phd::lacZYA) with Doc at 30°C
The Phd-LacZ fusion with Doc is not degraded at 30°C. If degradation required the
presence of Doc and was seen at this temperature, the specific activity of the wild type
strains containing ClpXP would be less than the specific activity seen in the strains
containing a ClpXP mutant. There was no significant difference between the wild type
strains and the mutants either with or without arabinose indicating that degradation was
not taking place.
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3.5

Phd is Not Degraded in the λRDM12(Pr92-lacZYA) Background
The possibility was considered that because the λmertz30(Ptac-phd::lacZYA)

protein product was a fusion, it could not be degraded by ClpXP. Therefore, a different
β-galactosidase assay design was used that employed unaltered lacZYA. This was carried
out using λRDM12(Pr92-lacZYA), which contained the P1 addiction promoter
transcriptionally fused to lacZ. Since λRDM12(Pr92-lacZYA) does not provide a source
of Phd like λmertz30 did, an alternative source of Phd must be provided to strains
utilizing the λRDM12 background.
Previous β-galactosidase assay experiments utilizing λRDM12 demonstrated that
Phd binds the P1 promoter to repress its own transcription at least 10-fold when
compared to the vector control. This was measured by a decrease in specific activity of
strains containing Phd (Magnuson, Lehnherr et al., 1996). The specific activity indicated
the level of lacZ expression from the P1 promoter. If ClpXP is degrading Phd then there
should be more Phd in strains containing a ClpXP knockout mutant when compared to
strains containing ClpXP. The more Phd there is, the greater the repression, which would
be represented by an even greater decrease in specific activity in strains containing a
ClpXP knockout mutant compared to strains containing ClpXP. Therefore, this provides
a means to use a β-galactosidase assay to test for degradation indirectly by testing for
repression. The strains utilized for the β-galactosidase repression assay are presented in
Table 3.7.
As seen in Table 3.8 and Figure 3.5, the results of two β-galactosidase repression
assays performed at 30°C showed that the specific activity was decreased in strains
containing Phd when compared to the vector strains as expected. However, only one of
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Table 3.7
Strains used in β-galactosidase Repression Assay in Section 3.5
The lac repressor was provided in all cases by placIq

Strain

LacZ Source

Phd source
(or vector)

ClpXP Phenotype

NM034

λRDM12(Pr92-lacZYA)

pKK223-3
(Ptac vector)

ClpXP+

NM074

λRDM12(Pr92-lacZYA)

pKK223-3
(Ptac vector)

ClpP-

NM035

λRDM12(Pr92-lacZYA)

Ptac-phd

ClpXP+

NM075

λRDM12(Pr92-lacZYA)

Ptac-phd

ClpP-

the trials showed the expected even greater decrease in specific activity in a strain with
Phd and a protease mutant but the difference wasn’t significant. These results were not
expected and indicated that Phd was not being degraded. As hypothesized when
λmertz30 was used, Doc might be required for ClpXP to degrade Phd so this was tested
next.
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Table 3.8
β-galactosidase Repression Assay of λRDM12(Pr92-lacZYA) with Phd at 30°C
Greater repression was said to be occurring if the mean specific activity decreased in
strains containing Phd and a protease mutant even more than it did in strains containing
Phd and ClpXP. There was no greater increase in repression observed in strains
containing Phd and a protease mutant.

Trial
#

1

2

	
  

Strain

Contents

Protease
Phenotype

Mean
Specific
Activity

Standard
Deviation

NM034

pKK223-3 (Ptac vector)

ClpXP+

3168.82

218.46

NM074

pKK223-3 (Ptac vector)

ClpP-

3795.11

232.39

NM035

Ptac-phd

ClpXP+

402.75

38.83

NM075

Ptac-phd

ClpP-

794.82

140.13

NM034

pKK223-3 (Ptac vector)

ClpXP+

2068.75

115.69

NM074

pKK223-3 (Ptac vector)

ClpP-

1691.34

176.26

NM035

Ptac-phd

ClpXP+

371.88

4.43

NM075

Ptac-phd

ClpP-

241.42

11.99
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Mean Specific Activity (Miller Units)

Repression of the Pr92 promoter by Phd at 30°C
4500
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Figure 3.5: Specific Activity of λRDM12(Pr92-lacZYA) with Phd at 30°C
Phd is not degraded at 30° in the λRDM12(Pr92-lacZYA) background. If degradation
was happening at this temperature, there would be more Phd present so the specific
activity of the wild type strain with Phd and ClpXP would be more than the specific
activity of the strain with Phd and the knockout mutant. However, this was only true in
one of the trials and the difference was not significant, indicating that degradation was
not taking place.
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3.6

Doc is Not Needed for Degradation in the λRDM12(Pr92-lacZYA) Background
In order to determine if Doc was necessary for the degradation of Phd by ClpXP,

strains listed in Table 3.9 were used. Previous β-galactosidase assay experiments showed
that Doc enhanced Phd’s repression of the P1 promoter approximately 100-fold. This was
measured by a decrease in specific activity of strains containing Phd and Doc compared
to the vector control (Magnuson, Lehnherr et al., 1996). An even greater decrease in
specific activity should be seen in strains containing Phd and Doc without ClpXP when
compared to the decrease seen in specific activity of strains containing Phd and Doc with
ClpXP.

Table 3.9
Strains used in β-galactosidase Repression Assay in Section 3.6
The lac repressor was provided in all cases by placIq

	
  

Strain

LacZ Source

Phd/Doc source
(or vector)

ClpXP Phenotype

NM207

λRDM12(Pr92-lacZYA)

pGB2 (vector)

ClpXP+

NM223

λRDM12(Pr92-lacZYA)

pGB2 (vector)

ClpP-

NM208

λRDM12(Pr92-lacZYA)

pGB2-Ptac-phd

ClpXP+

NM224

λRDM12(Pr92-lacZYA)

pGB2-Ptac-phd

ClpP-

NM221

λRDM12(Pr92-lacZYA)

pGB2-Ptac-phd-doc

ClpXP+

NM225

λRDM12(Pr92-lacZYA)

pGB2-Ptac-phd-doc

ClpP-
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The results of this β-galactosidase repression assay performed at 30°C
demostrated that the specific activity was not decreased in strains that lacked the ClpXP
protease anymore than it was in strains where the ClpXP protease was present, as seen in
Table 3.10, Figure 3.6, and Figure 3.7. These results were not expected and seem to
indicate that Phd is not being degraded in strains where ClpXP is present. This might
also indicate that Doc is not required for, nor does it interfere with degradation. Another
possibility is that Phd and/or Doc must be in an autoregulated form in order for Phd to be
degraded by ClpXP, so this was tested next.

Table 3.10
β-galactosidase Repression Assay of λRDM12(Pr92-lacZYA) with Phd and Doc at
30°C
Greater repression was said to be occurring if the mean specific activity decreased in
strains containing Phd or Phd and Doc with a protease mutant even more than it did in
strains containing Phd or Phd and Doc with ClpXP. There was no greater increase in
repression observed in strains containing Phd or Phd and Doc with a protease mutant.

Strain

Contents

Protease
Phenotype

Mean SAd

SDe

NM207

pGB2 vector

ClpXP+

2636.78

171.3

NM223

pGB2 vector

ClpP-

2861.24

287.4

NM208

pGB2-Ptac-phd

ClpXP+

1030.02

115.47

NM224

pGB2-Ptac-phd

ClpP-

1109.38

140.68

NM221

pGB2-Ptac-phd-doc

ClpXP+

1.67

0.32

NM225

pGB2-Ptac-phd-doc

ClpP-

2.49

0.86
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Repression of the Pr92 promoter by Phd or Phd and Doc at 30°C

Mean Specific Activity (Miller Units)
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Figure 3.6: Specific Activity of λRDM12(Pr92-lacZYA) with Phd and Doc at 30°C
Phd is not degraded at 30°C in the λRDM12(Pr92-lacZYA) background in the presence
of Doc. If degradation was happening at this temperature, there would be more Phd
present so the specific activity of the wild type strain with Phd or Phd and Doc with
ClpXP would be more than the specific activity of the strain with Phd or Phd and Doc
and the knockout mutant. However, there were no significant differences between these
strains indicating that degradation was not taking place and that Doc was not a factor.
Since the specific activity of the strains with Phd and Doc were so much lower, they are
presented independently in Figure 3.7.
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Mean Specific Activity
(Miller Units)

Repression of the Pr92 promoter by Phd and
Doc at 30°C
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ClpP-

1
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Figure 3.7: Specific Activity of λRDM12(Pr92-lacZYA) with Phd and Doc at 30°C
Since the specific activity of the strains containing Phd and Doc were too low to be seen
in Figure 3.6, they are presented here.

3.7

Autoregulated Phd is Not Degraded at 30°C in the λRDM12(Pr92-lacZYA)
Background
Instead of using a source of Phd and/or Doc from an artificial promoter, an

autoregulated form from pGB2ts was utilized. The strains used for this assay are
presented in Table 3.11. Like the previous assay, strains containing Phd and Doc should
show an increase in repression as measured by a decrease in specific activity compared to
vector strains. Also, strains without ClpXP should show an even greater increase in
repression.
As seen in Table 3.12, Figure 3.8, and Figure 3.9, the results of this
β-galactosidase repression assay performed at 30°C illustrates that the addition of Phd
and Doc does decrease specific activity as expected but there is not an even greater
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Table 3.11
Strains used in β-galactosidase Repression Assay in Section 3.7

Strain

LacZ Source

Phd/Doc source
(or vector)

ClpXP Phenotype

NM184

λRDM12(Pr92-lacZYA)

pGB2ts (vector)

ClpXP+

NM196

λRDM12(Pr92-lacZYA)

pGB2ts (vector)

ClpX-

NM198

λRDM12(Pr92-lacZYA)

pGB2ts (vector)

ClpP-

NM185

λRDM12(Pr92-lacZYA)

pGB2ts::phd-doc

ClpXP+

NM197

λRDM12(Pr92-lacZYA)

pGB2ts::phd-doc

ClpX-

NM199

λRDM12(Pr92-lacZYA)

pGB2ts::phd-doc

ClpP-

Table 3.12
β-galactosidase Repression Assay of λRDM12(Pr92-lacZYA) with autoregulated
Phd and Doc at 30°C
Greater repression was said to be occurring if the mean specific activity decreased in
strains containing Phd and Doc with a protease mutant even more than it did in strains
containing Phd and Doc with ClpXP. There was no greater increase in repression
observed in strains containing Phd and Doc with a protease mutant.

	
  

Strain

Contents

ClpXP Phenotype

Mean Specific
Activity

Standard
Deviation

NM184

pGB2ts

ClpXP+

1727.4

83.98

NM196

pGB2ts

ClpX-

1761.31

190.16

NM198

pGB2ts

ClpP-

1985.96

313.02

NM185

pGB2ts::phd-doc

ClpXP+

2.64

0.49

NM197

pGB2ts::phd-doc

ClpX-

2.12

0.55

NM199

pGB2ts::phd-doc

ClpP-

2.56

0.24
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Mean Specific Activity (Miller Units)

Repression of the Pr92 promoter by Phd and
Doc at 30°C
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Figure 3.8: Specific Activity of λRDM12(Pr92-lacZYA) autoregulated at 30°C
Phd is not degraded in an autoregulated form in the λRDM12(Pr92-lacZYA) background
at 30°C. If degradation was happening at this temperature, there would be more Phd
present so the specific activity of the wild type strain with Phd, Doc, and ClpXP would be
more than the specific activity of the strain with Phd and Doc and the knockout mutants.
However, there were no significant differences between these strains indicating that
degradation was not taking place. Since the specific activity of the strains with Phd and
Doc were so much lower, they are presented independently in Figure 3.9.
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Repression of the Pr92 promoter by Phd and Doc at 30°C
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Figure 3.9: Specific Activity of λRDM12(Pr92-lacZYA) autoregulated at 30°C
Since the specific activity of the strains containing Phd and Doc were too low to be seen
in Figure 3.8, they are presented here.
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decrease in specific activity in strains that are ClpX- or ClpP-. This seems to indicate that
degradation of Phd is not occurring. However, this could indicate that degradation does
not occur at 30°C. The effects of temperature in the degradation of Phd by ClpXP in an
autoregulated system were examined next.

3.8

Natural Phd is Not Degraded at 42°C in the λRDM12(Pr92-lacZYA)
Background
In order to test if Phd is degraded at 42°C, the source for Phd and/or Doc cannot

come from pGB2ts since it is a thermosensitive plasmid. Instead, P1 was used since it is
the natural source of Phd and can withstand the increased temperature. The source of
lacZ was still λRDM12(Pr92-lacZYA). The strains used in this temperature affect
experiment are presented in Table 3.13. Strains containing Phd and Doc from P1 should
show an increase in repression as measured by a decrease in specific activity and strains
without ClpXP should show an even greater decrease in specific activity.
The results of the β-galactosidase repression assay performed at 42°C
demonstrated that P1 greatly reduces the specific activity of strains containing it just as
expected and can be seen in Table 3.14, Figure 3.10, and Figure 3.11. The results also
indicate that there was no real difference between the Clp+ strains and the Clp- strains, so
degradation was still not occurring. λRDM11(P-phd(all)-lacZYA) is another lacZ fusion
that contains both P1’s natural promoter and the full coding sequence of Phd, so this was
tested next.
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Table 3.13
Strains used in β-galactosidase Repression Assay in Section 3.8

	
  

Strain

LacZ Source

Phd/Doc source

NM058

λRDM12(Pr92-lacZYA)

ClpXP+

NM065

λRDM12(Pr92-lacZYA)

ClpX-

NM077

λRDM12(Pr92-lacZYA)

ClpP-

NM186

λRDM12(Pr92-lacZYA)

P1 Cm

ClpXP+

NM148

λRDM12(Pr92-lacZYA)

P1 Cm

ClpX-

NM187

λRDM12(Pr92-lacZYA)

P1 Kan

ClpXP+

NM150

λRDM12(Pr92-lacZYA)

P1 Kan

ClpP-

75	
  

ClpXP Phenotype

Table 3.14
β-galactosidase Repression Assay of λRDM12(Pr92-lacZYA) with P1 at 42°C
Greater repression was said to be occurring if the mean specific activity decreased in
strains containing P1 with a protease mutant even more than it did in strains containing
P1 with ClpXP. There was no greater increase in repression observed in strains
containing Phd and Doc with a protease mutant.

Trial #

1

2

	
  

NM058

Protease
Phenotype
ClpXP+

Mean Specific
Activity
2167.52

Standard
Deviation
100.07

NM065

ClpX-

2163.54

267.81

NM077

ClpP-

1958.38

207.71

Strain

Contents

NM186

P1 Cm

ClpXP+

56.72

6.97

NM148

P1 Cm

ClpX-

56.02

9.66

NM187

P1 Kan

ClpXP+

81.66

7.07

NM150

P1 Kan

ClpP-

64.8

4.2

NM058

ClpXP+

1794.26

320.1

NM065

ClpX-

1867.41

221.24

NM077

ClpP-

1659.93

212.13

NM186

P1 Cm

ClpXP+

43.16

3.94

NM148

P1 Cm

ClpX-

48.58

13.04

NM187

P1 Kan

ClpXP+

55.2

10.9

NM150

P1 Kan

ClpP-

51.2

9.3
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Degradation of Phd from P1 at 42°C
Mean Specific Activity (MIller Units)
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Figure 3.10: Specific Activity of λRDM12(Pr92-lacZYA) with P1 at 42°C
Phd from P1 is not degraded in the λRDM12(Pr92-lacZYA) background at 42°C. If
degradation was happening at this temperature, there would be more Phd present so the
specific activity of strains with P1 and ClpXP would be more than the specific activity of
the strains with P1 and the knockout mutants. However, there was no significant
difference between these strains indicating that degradation was not taking place. Since
the specific activity of the strains with P1 were so much lower and difficult to compare
on this graph, they are presented independently in Figure 3.11.
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Mean Specific Activity (MIller Units)
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Figure 3.11: Specific Activity of λRDM12(Pr92-lacZYA) with P1 at 42°C
Since the specific activity of the strains containing P1 were too low to be seen in Figure
3.10, they are presented here.
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3.9

Natural Phd is Degraded at 42°C in the λRDM11(P-phd(all)-lacZYA)
Background
Since degradation of Phd was not detected in strains that contained either the

λmertz30(Ptac-phd::lacZYA) or the λRDM12(Pr92-lacZYA) backgrounds, strains with the
λRDM11(P-phd(all)-lacZYA) background will be used. This background contains the P1
natural promoter, Pr92, plus the full coding sequence of Phd transcriptionally fused to
lacZYA. The strains used in this experiment are presented in Table 3.15. Strains
containing Phd and Doc from P1 should show an increase in repression as measured by a
decrease in specific activity and strains without ClpXP should show an even greater
decrease in specific activity.

Table 3.15
Strains used in β-galactosidase Repression Assays in Section 3.9 and 3.10

	
  

Strain

LacZ/Phd Source

Phd/Doc source

NM059

λRDM11(P-phd(all)-lacZYA)

ClpXP+

NM069

λRDM11(P-phd(all)-lacZYA)

ClpX-

NM078

λRDM11(P-phd(all)-lacZYA)

ClpP-

NM188

λRDM11(P-phd(all)-lacZYA)

P1 Cm

ClpXP+

NM149

λRDM11(P-phd(all)-lacZYA)

P1 Cm

ClpX-

NM203

λRDM11(P-phd(all)-lacZYA)

P1 Kan

ClpXP+

NM151

λRDM11(P-phd(all)-lacZYA)

P1 Kan

ClpP-
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ClpXP Phenotype

As seen in Table 3.16 and Figure 3.12, the results of the β-galactosidase
repression assay performed at 42°C showed that P1 greatly reduces the specific activity
of strains containing it as expected. Also, removing either ClpXP subunit did somewhat
reduce the specific activity. These results indicate that some measurable degradation was
occurring. This assay was performed at 42°C though, so performing it at 30°C might
allow better degradation to be observed.

Table 3.16
β-galactosidase Repression Assay of λRDM11(P-phd(all)-lacZYA) with P1 at 42°C
Greater repression was said to be occurring if the mean specific activity decreased in
strains containing P1 with a protease mutant even more than it did in strains containing
P1 with ClpXP. These results show that there was greater repression in the ClpX- strain
with P1 Cm but there was not a significant difference in the ClpP- strain. There was also
an unexpected decrease in specific activity of the vector controls containing a protease
mutant.

Strain

	
  

Contents

Protease Phenotype

Mean Specific Standard
Activity
Deviation
2080.92
35.63

NM059

ClpXP+

NM069

ClpX-

1300.18

131

NM078

ClpP-

1118.63

64.5

NM188

P1 Cm

ClpXP+

174.49

21.26

NM149

P1 Cm

ClpX-

109.76

8.61

NM203

P1 Kan

ClpXP+

146.1

13.06

NM151

P1 Kan

ClpP-

122.34

27.56
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Degradation of Phd from P1 at 42°C
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Figure 3.12: Specific Activity of λRDM11(P-phd(all)-lacZYA) with P1 at 42°C
Phd is somewhat degraded in the λRDM11(P-phd(all)-lacZYA) background at 42°C with
P1. If degradation was happening at this temperature, there would be more Phd present
so the specific activity of strains with P1 and ClpXP would be more than the specific
activity of the strains with P1 and the knockout mutants and those results were seen just
not to the extent as expected. There was an unexpected decrease in specific activity of
the vector strains with a protease mutant.
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3.10

Natural Phd is Degraded at 30°C in the λRDM11(P-phd(all)-lacZYA)
Background
Since previous results indicated that there was some degradation observed when

using the λRDM11(P-phd(all)-lacZYA) background at 42°C, this next assay was
performed at 30°C in order to determine if temperature played a role in the rate of
degradation of Phd. The strains presented previously in Table 3.15 were used in this
experiment. Again, strains containing Phd and Doc from P1 should show an increase in
repression as measured by a decrease in specific activity and strains without ClpXP
should show an even greater decrease in specific activity.
The results of this β-galactosidase repression assay performed at 30°C confirmed
that P1greatly reduces the specific activity of strains containing it at this temperature as
well. The results are presented in Table 3.17 and Figure 3.13. The results also showed
that removing either ClpXP subunit does reduce the specific activity. This reduction in
specific activity is consistent with the results seen when this experiment was performed at
42°C. The results of the experiments at both 30°C and 42°C indicate that some
measurable degradation is occurring and that temperature does not influence the rate of
degradation in the λRDM11 background.
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Table 3.17
β-galactosidase Repression Assay of λRDM11(P-phd(all)-lacZYA) with P1 at 30°C
Greater repression was said to be occurring if the mean specific activity decreased in
strains containing P1 with a protease mutant even more than it did in strains containing
P1 with ClpXP. These results show that there was greater repression in the ClpX- strain
with P1 Cm but there was not a significant difference in the ClpP- strain. There was also
a decrease in specific activity of the vector controls containing a protease mutant similar
to what was seen when this experiment was performed at 42°C.

NM059

ClpXP+

Mean Specific
Activity
2581.96

NM069

ClpX-

1656.25

92.73

NM078

ClpP-

1438.95

94.58

Strain

	
  

Contents

Protease Phenotype

Standard
Deviation
159.26

NM188

P1 Cm

ClpXP+

197.26

23.03

NM149

P1 Cm

ClpX-

112.84

14.63

NM203

P1 Kan

ClpXP+

137.62

11.41

NM151

P1 Kan

ClpP-

121.25

8.87
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Degradation of Phd from P1 at 30°C
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Figure 3.13: Specific Activity of λRDM11(P-phd(all)-lacZYA) with P1 at 30°C
Phd is somewhat degraded in the λRDM11(P-phd(all)-lacZYA) background at 30°C with
P1. If degradation was happening at this temperature, there would be more Phd present
so the specific activity of strains with P1 and ClpXP would be more than the specific
activity of the strains with P1 and the knockout mutants and those results were seen just
not to the extent as expected. There was a decrease in specific activity of the vector
strains with a protease mutant similar to what was observed when this experiment was
performed at 42°C.
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3.11

Phd is Diluted Before it is Degraded
The λRDM11(P-phd(all)-lacZYA) background contains a λ phage encoding the P1

promoter, Pr92, fused to the full coding sequence of phd followed by lacZYA and thus
provides a source for LacZ and a source for low-level expression of Phd. Adding P1 to
strains containing this background provides a source for Doc and an additional source for
Phd. Previous testing of strains containing the λRDM11(P-phd(all)-lacZYA) background
and P1 suggested that some measurable degradation was occurring. In order to determine
if the amount of Phd affected degradation, testing of strains containing just this
background with and without ClpXP were performed. Since Phd represses its own
transcription, a decrease in specific activity in strains without ClpXP as compared to
strains with ClpXP should be observed. All strains used in this assay are presented in
Table 3.18.

Table 3.18
Strains used in β-galactosidase Repression Assay in Section 3.11

Strain

LacZ/Phd source

ClpXP Phenotype

NM059

λRDM11(P-phd(all)-lacZYA)

ClpXP+

NM069

λRDM11(P-phd(all)-lacZYA)

ClpX-

NM078

λRDM11(P-phd(all)-lacZYA)

ClpP-

The results of this β-galactosidase repression assay performed at 30°C are
presented in Table 3.19 and Figure 3.14. The results demonstrate that the removal of
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Table 3.19
β-galactosidase Repression Assay of λRDM11(P-phd(all)-lacZYA) at 30°C
Repression was said to be occurring if the mean specific activity decreased in strains with
a protease mutant. The results showed that there was a decrease in all three trials.

Trial #

1

2

3

NM059

Protease
Phenotype
ClpXP+

Mean Specific
Activity
2451.86

Standard
Deviation
132.61

NM069

ClpX-

1756.69

32.47

NM078

ClpP-

1380.76

122.43

NM059

ClpXP+

2658.85

142.05

NM069

ClpX-

1817.65

145.99

NM078

ClpP-

1777.98

41.18

NM059

ClpXP+

2581.96

159.26

NM069

ClpX-

1656.25

92.73

NM078

ClpP-

1438.95

94.58

Strain

either ClpXP subunit does decrease the specific activity when compared to the vector
strain. This indicates that the promoter is repressed more in strains without ClpXP.
Since Phd is not degraded in strains without ClpXP, there should be more Phd available
to better repress the promoter and the results indicate this is true.
One thing to note is that the only instances that measurable degradation was
indicated by a difference in specific activities between ClpXP+ strains and ClpXP- strains
were when the λRDM11(P-phd(all)-lacZYA) background was included. When this was
used the levels of Phd were relatively low. This suggests that Phd was not actually
degraded until the concentration fell to a low level, therefore Phd might have to be
diluted before it is degraded.
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Mean Specific Activity (Miller Units)
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Figure 3.14: Specific Activity of λRDM11(P-phd(all)-lacZYA) at 30°C
Phd is degraded in the λRDM11(P-phd(all)-lacZYA) background at 30°C. If degradation
was seen at this temperature, the specific activity of the wild type strain would be more
than the specific activity seen in the mutant strains and that was observed in all 3 trials.
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3.12

Known Accessory Specificity Factors, RssB and SspB, Are Not Required for
Degradation
Previous addiction assays described in section 3.1 established that the P1 system

is addictive and that ClpXP is required for both the addictive response and proteolysis.
Degradation of some ClpXP substrates requires additional or accessory specificity
factors. One such accessory specificity factor is the response regulator protein,
RssB (Becker, Klauck et al., 1999). Another accessory specificity factor is the stringent
starvation protein, SspB (Levchenko, Seidel et al., 2000). It is possible that either one of
these factors could be required for the ClpXP degradation of Phd.
Utilizing the two thermosensitive plasmids, pGB2ts and pGB2ts::phddoc, along
with known accessory specificity factors of ClpXP, allows detection of the addictive
phenotype and the capability to determine if these factors were required for the ClpXP
degradation of Phd. Strains containing either the addictive or non-addictive plasmids
along with specific gene mutations were assayed for their ability to disrupt addiction.
The gene mutations tested for were sspB::kan, rssB::Tn10, and the double mutation
including both sspB::kan and rssB::Tn10. The clpX::kan mutation was included as an
additional negative control. As seen in Table 3.20, the results of three repetitive addiction
assays revealed that a mutation in clpX did relieve addiction as expected but that
mutations in rssB and/or sspB did not relieve addiction. This indicates that neither RssB
nor SspB are required for proteolysis of Phd by ClpXP.
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Table 3.20
Addiction Assay of Accessory Specificity Factors

Strain

Description
Plasmid

Chromosomal
Marker

NM239

pGB2ts

NM088

pGB2ts

rssB::Tn10

NM090

pGB2ts

sspB::kan

NM092

pGB2ts

rssB::Tn10
& sspB::kan

NM018

pGB2ts

clpX::kan

NM240

pGB2ts::
phd-doc

NM089

pGB2ts::
phd-doc

rssB::Tn10

NM091

pGB2ts::
phd-doc

sspB::kan

NM093

pGB2ts::
phd-doc

rssB::Tn10
& sspB::kan

NM019

pGB2ts::
phd-doc

clpX::kan

CFU/mLa

Exp
#

42°C

30°C

1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3

70 x 108
94 x 108
74 x 108
89 x 108
80 x 108
36 x 108
83 x 108
71 x 108
54 x 108
53 x 108
100 x 108
99 x 108
49 x 108
56 x 108
58 x 108
18 x 107
10 x 106
38 x 107
34 x 106
7 x 106
7 x 106
70 x 106
7 x 106
16 x 106
19 x 106
5 x 106
5 x 106
47 x 108
68 x 108
49 x 108

64 x 108
89 x 108
88 x 108
69 x 108
88 x 108
55 x 108
108 x 108
66 x 108
64 x 108
56 x 108
81 x 108
98 x 108
49 x 108
87 x 108
46 x 108
120 x 108
64 x 108
84 x 108
87 x 108
87 x 108
79 x 108
76 x 108
96 x 108
91 x 108
54 x 108
92 x 108
73 x 108
31 x 108
53 x 108
52 x 108

EOPb
1.094
1.056
0.841
1.290
0.909
0.655
0.769
1.076
0.844
0.946
1.235
1.010
1.000
0.644
1.261
0.015
0.002
0.045
0.004
0.001
0.001
0.009
0.001
0.002
0.004
0.001
0.001
1.516
1.283
0.942

Resultsc
Not
Addictive
Not
Addictive
Not
Addictive
Not
Addictive
Not
Addictive
Addictive

Addictive

Addictive

Addictive
Not
Addictive

a. CFU/mL refers to colony forming units per milliliter
b. EOP refers to Efficiency of Plating – this was determined by dividing the
CFU/mL at 42°C by CFU/mL at 30°C
c. Addiction was known to occur when constructs containing pGB2ts::phd-doc
approached zero
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CHAPTER 4

CONCLUSION

4.1

Summary and Areas for Further Study
Several theories exist as to the biological significance of toxin-antitoxin systems.

TA systems can be classified as parasitic elements because they are dependent on a host
cell for replication and expression, yet they cause cell death when they are lost, but TA
systems can also increase the relative fitness of their host by eradicating competing
plasmids in their bacterial progeny through post-segregational killing (Van Melderen and
Saavedra De Bast, 2009). Bacteria often grow in dense, multicellular communities
known as biofilms (Kolter and Losick, 1998). TA systems have been linked to biofilm
formation. The gene, mqsR, which is part of the MqsR/MqsA TA system, is associated
with both motility and quorum sensing which influence biofilm formation (Gonzalez
Barrios, Zuo et al., 2006). Biofilm formation in E. coli was found to decrease 8 hours
after five TA systems were deleted revealing that they also play a role in biofilm
formation (Ren, Bedzyk et al., 2004). TA systems have been identified with persister
cells, which are a group of cells that are still viable even after exposure to high
concentrations of antibiotics (Gefen and Balaban, 2009). TA systems are believed to
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play a major role in persister formation by inducing states of dormancy that allow the
bacterial cells to escape the antibiotic effects (Jayaraman, 2008).
The continued study of TA systems could lead to more information about their
biological significance. The study of each individual TA system could also lead to a
greater understanding of the roles of the toxin and antitoxin. This thesis focused on the
ClpXP mediated degradation of Phd, which contributes greatly to the overall state of the
P1 operon. If you consider the role of the antitoxin, Phd, in regulation it can be shown
that in steady-state conditions, Phd is the vital component as seen in the following
equation:

It is not currently known how ClpXP recognizes and degrades Phd. However, it
is known how ClpXP recognizes and degrades a number of its other substrates and based
on that, certain inferences can be made about the possible ways ClpXP might recognize
and degrade Phd. Table 1.3 lists three N-terminal motifs of substrates known to be
recognized by ClpXP. The motif identified as N-motif 3 fits the concensus
Ø-X-polar-X-polar-X-basic-polar, where Ø is a hydrophobic amino acid and X is any
amino acid. Table 4.1 illustrates how the first eight amino acids of the N-terminal
sequence of Phd match N-motif 3 and could be the portion of Phd’s sequence that ClpXP
recognizes and degrades.
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Table 4.1
N-motif 3 and Phd Sequence Comparison
This is a comparison between the ClpXP recognition motif designated N-motif 3 and the
first eight amino acids of the N-terminal end of the Phd protein
(Ø indicates a hydrophobic amino acid; X indicates any amino acid)

N-motif 3

Phd Sequence

Comments

Ø

M

Methionine is hydrophobic

X

Q

Glutamine

Polar

S

Serine is polar

X

I

Isoleucine

Polar

N

Asparagine is polar

X

F

Phenylalanine

Basic

R

Arginine is basic

Polar

T

Threonine is polar

The addiction assay experiments described in this thesis demonstrated that Phd
degradation by ClpXP is not dependent upon the known accessory specificity factors,
RssB and/or SspB. Since SspB is important for degradation of ssrA-tagged substrates,
our results would seem to indicate that ssrA is not required for the ClpXP degradation of
Phd either. An addiction assay performed testing a mutation in ssrA confirmed this
(Hung, 2007). Since Phd degradation does not rely upon RssB, SspB, nor the ssrAtagging system, ClpXP must directly recognize Phd or must utilize another currently
unknown accessory specificity factor.
The results of β-galactosidase repression and degradation assays described in this
thesis indicate that neither temperature nor the presence or absence of Doc is a factor
influencing degradation of Phd by ClpXP. In fact, the only consistent observation of
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degradation was seen when Phd was at low levels suggesting that before Phd is degraded
by ClpXP, it might first need to be diluted. However, it must also be considered that
degradation was not detectable by the β-galactosidase repression assay because the high
concentration of Phd led to saturation of the operator and therefore repression of
transcription. This assay would then only be able to detect degradation when the levels
of Phd fell low enough to affect operator binding.
ClpXP is known to degrade Phd but ClpXP could also play a role in the action of
the toxin protein, Doc. For example, Doc might phosphorylate its target and ClpXP
recognizes this phosphorylated target as a degradation signal and subsequently degrades
the target. If the target played a vital role in protein synthesis and was no longer able to
fulfill this role then the cell would ultimately arrest. When low levels of Phd are present
in the cell, there is not as much Phd available to neutralize Doc, so it would be free to
phosphorylate its target, but if in this case a ClpXP mutant was also utilized and no
degradation was occurring anyway then it would be impossible to tell if this effect was
due to Phd only being degraded at low levels or if the effect was due to ClpXP not
degrading the phosphorylated target.
Phd and/or Doc can be found in several different conformations within a cell.
Phd and Doc can both be found in the monomeric form, they can be found bound
together in two different conformations to form a heterodimer, and Phd can also form a
homodimer. There are also instances where a homodimer of Phd can bind with Doc in
two different conformations to form heterotrimers. Other multimeric forms have also
been identified (Balasubramanian, 2010). When the concentration of Phd is relatively
high inside a cell there are more dimers, trimers, and multimers formed and when the
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concentration of Phd is relatively low inside a cell there are mostly monomers present
(Magnuson and Yarmolinsky, 1998). My results are consistent with the hypothesis that
Phd is only degraded when it is at low concentrations and therefore, only degraded in the
monomeric form. This “dilution before degradation” model is illustrated in Figures 4.1
and 4.2.
There are other examples of ClpXP only degrading its substrates when they are in
specific monomeric or oligomeric forms. One such example is the ClpXP substrate
UmuD’ from the DNA polymerase, pol V found in E. coli (Gonzalez, Rasulova et al.,
2000). UmuD is synthesized first as a pro-protein and then once it is processed it
becomes stable and known as UmuD’. In vivo, when UmuD and UmuD’ are found
together they interact to form heterodimers and it is only in this confirmation when
UmuD’ becomes susceptible to ClpXP degradation. There are also two separate studies
evaluating the ClpXP degradation of SsrA-tagged proteins. In one study, it was
determined that ClpXP only degrades the subunit with the SsrA tag when it is interacting
with a non-covalently linked heterodimeric protein (Burton, Siddiqui et al., 2001). A
second study confirmed this observation by demonstrating that ClpXP requires both
subunits of a heterodimeric protein to contain an SsrA tag in order for them both to be
degraded (Sharma, Hoskins et al., 2005).
Future experiments could focus on determining if the dilution before degradation
hypothesis is valid. Since Phd might need to be diluted before it is degraded, some future
experiments could include utilizing known dimerization mutants of Phd. The
Ptac-phdV37A, Ptac-phdI38A, Ptac-phdV39A, Ptac-phdF44A, and the Ptac-phdY47A
mutants were demostrated to be dimerization deficient (Siegel, 2008). Utilizing strains
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Figure 4.1: Symbols for Dilution Before Degradation Model
The key symbols used in the dilution before degradation model include a circle with a
triangle cutout indicating the protease, ClpXP. Phd monomers are shown as single,
shaded, right triangles while Phd homodimers are displayed as double right triangles. A
line with tick marks indicates the P1 operator-promoter binding site.
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Figure 4.2: Dilution Before Degradation Model
When there is a high concentration of Phd, the dimeric form predominates and binds to
the promoter to repress transcription. Even if degradation is occurring, there is still a
large buffer of dimers that is able to maintain repression, therefore degradation is difficult
to detect. As the concentration of Phd decreases (i.e. dilution occurs) the proportion of
monomers increases and degradation can then be observed.
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containing these mutants would prevent dimerization of Phd, thus allowing
experimentation to determine if degradation is increased compared to control strains.
Another approach would be to utilize radiolabelled Phd at both high and low
concentrations in order to confirm the hypothesis that dilution must occur before
degradation takes place. Since the ClpXP degradation of Phd is a vital component in the
P1 plasmid addiction system, understanding how and when ClpXP degrades Phd will
improve our understanding of the regulation and control of this system.
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APPENDIX A

β-galactosidase Assay Record Sheets
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TABLE A.1
β-galactosidase Assay Record Sheet for Section 3.2
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TABLE A.2
β-galactosidase Assay Record Sheet for Section 3.3 Trial 1
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TABLE A.3
β-galactosidase Assay Record Sheet for Section 3.3 Trial 2
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TABLE A.4
β-galactosidase Assay Record Sheet for Section 3.3 Trial 3
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TABLE A.5
β-galactosidase Assay Record Sheet for Section 3.3 Trial 4
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TABLE A.6
β-galactosidase Assay Record Sheet for Section 3.4 Trial 1
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TABLE A.7
β-galactosidase Assay Record Sheet for Section 3.4 Trial 2
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TABLE A.8
β-galactosidase Assay Record Sheet for Section 3.4 Trial 3
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TABLE A.9
β-galactosidase Assay Record Sheet for Section 3.5 Trial 1
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TABLE A.10
β-galactosidase Assay Record Sheet for Section 3.5 Trial 2
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TABLE A.11
β-galactosidase Assay Record Sheet for Section 3.6
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TABLE A.12
β-galactosidase Assay Record Sheet for Section 3.7
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TABLE A.13
β-galactosidase Assay Record Sheet for Section 3.8 Trial 1
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TABLE A.14
β-galactosidase Assay Record Sheet for Section 3.8 Trial 2
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TABLE A.15
β-galactosidase Assay Record Sheet for Section 3.9
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TABLE A.16
β-galactosidase Assay Record Sheet for Section 3.10
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TABLE A.17
β-galactosidase Assay Record Sheet for Section 3.11 Trial 1
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TABLE A.18
β-galactosidase Assay Record Sheet for Section 3.11 Trial 2
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TABLE A.19
β-galactosidase Assay Record Sheet for Section 3.11 Trial 3
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